<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005581.pub2" GROUP_ID="SCHIZ" ID="574803091212221241" MERGED_FROM="" MODIFIED="2012-04-26 15:55:52 +0200" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-04-26 14:54:39 +0100" NOTES_MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-04-26 15:55:52 +0200" MODIFIED_BY="Claire Irving">
<TITLE>Antidepressants for the negative symptoms of schizophrenia</TITLE>
<CONTACT MODIFIED="2012-04-26 15:55:52 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT><ORGANISATION/><ADDRESS_1>Semmelweisstr. 10</ADDRESS_1><CITY>04103 Leipzig</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-04-26 15:55:52 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT><ORGANISATION/><ADDRESS_1>Semmelweisstr. 10</ADDRESS_1><CITY>04103 Leipzig</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-04-26 14:52:21 +0100" MODIFIED_BY="Bethany York" NOTES="&lt;p&gt;Minor update: 5/22/06&lt;/p&gt;" NOTES_MODIFIED="2012-04-26 14:52:21 +0100" NOTES_MODIFIED_BY="Bethany York">
<UP_TO_DATE>
<DATE DAY="24" MONTH="5" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="5" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="5" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2012-04-26 14:54:39 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-04-26 14:54:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>Additional table linked to text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-04-26 14:51:32 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-04-26 14:51:32 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>German Federal Ministry for Education and Research (BMBF) (grant 01 GI 993x)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-04-26 14:51:15 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-22 15:04:57 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-22 15:04:57 +0100" MODIFIED_BY="[Empty name]">Antidepressants for the negative symptoms of schizophrenia</TITLE>
<SUMMARY_BODY>
<P>Guidelines recommend adding antidepressants to antipsychotics for people with schizophrenia who have persisting negative symptoms. The combination of antipsychotics and antidepressants may be more effective in treating negative symptoms of schizophrenia than antipsychotics alone, but the quality of information is currently too limited to come to any firm conclusions.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Negative symptoms are common in people with schizophrenia and are often difficult to treat with antipsychotic drugs. Treatment often involves the use of various add-on medications such as antidepressants.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To review the effects of the combination of antipsychotic and antidepressant drug treatment for management of negative symptoms in schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Schizophrenia Group's register (January 2004). We also contacted authors of included studies in order to identify further trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included all randomised controlled trials comparing antipsychotic and antidepressant combinations with antipsychotics alone for the treatment of prominent negative symptoms in schizophrenia and/or schizophrenia-like psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Working independently, we selected and critically appraised studies, extracted data and analysed on an intention-to-treat basis. Where possible and appropriate we calculated the relative risk RR) and their 95% confidence intervals (CI), with the number needed to treat (NNT).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included five studies (all short-term, total N=190). We found no significant difference for 'leaving the study early for any reason' between the antipsychotic plus antidepressant combination and the control group (n=90, 3 RCTs, RR 3.0 CI 0.35 to 26.04). Leaving early due to adverse events (n=64, 2 RCTs, RR 5.0 CI 0.26 to 97.0) and leaving the study early due to inefficacy (n=34, 1 RCT, RR 3.0 CI 0.13 to 68.84) also showed no significant difference between the two treatment groups. In terms of clinical response, participants treated with the antipsychotic plus antidepressant medications showed a statistically significant greater improvement (n=30, 1 RCT, WMD -1.0 CI -1.61 to -0.39) and showed a significantly lower severity at endpoint (n=30, 1 RCT, WMD -0.9 CI -1.55 to -0.25) on the Clinical Global Impression Scale than those treated with antipsychotics alone. More people allocated to combination therapy had a clinically significant improvement in negative symptoms compared with those given antipsychotics and placebo (n=60, 2 RCTs, RR 0.56 CI 0.32 to 0.97, NNT 3 CI 3 to 34). Significant differences in favour of the combination therapy were seen in different aspects of negative symptoms: 'affective flattening' (n=30, 1 RCT, WMD -7.0 CI -10.37 to -3.63), 'alogia' (n=26, 1 RCT, WMD -3.00 CI -5.14 to -0.86) and 'avolition' (n=30, 1 RCT, WMD -3.0 CI -5.04 to -0.96). No statistically significant difference was found between treatment groups in regards to the outcome 'at least one adverse event' (n=84, 2 RCTs, RR 1.80 CI 0.66 to 4.90). For movement disorders and other adverse effects, no statistically significant differences were found in any of the studies that provided usable data on these outcomes. There are no data at all on outcomes such as compliance, cost, social and cognitive functioning, relapse, recurrence of negative symptoms, rehospitalisation or quality of life. There are no medium or long term data.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The combination of antipsychotics and antidepressants may be effective in treating negative symptoms of schizophrenia, but the amount of information is currently too limited to allow any firm conclusions. Large, pragmatic, well-designed and reported long term trials are justified.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-04-26 14:51:15 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Antipsychotic medication is effective for the treatment of the so-called 'positive' symptoms of schizophrenia (symptoms that exceed normal experience), such as false, fixed beliefs (delusions) and perceptions without a cause (hallucinations) (<LINK REF="REF-Joy-2002" TYPE="REFERENCE">Joy 2002</LINK>, <LINK REF="REF-Thornley-2002" TYPE="REFERENCE">Thornley 2002</LINK>). It has been stated, however, that treatment with antipsychotics is less effective for so-called 'negative' symptoms of schizophrenia (<LINK REF="REF-Crow-1980" TYPE="REFERENCE">Crow 1980</LINK>, <LINK REF="REF-Andreasen-1985" TYPE="REFERENCE">Andreasen 1985</LINK>, <LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). Contrary to positive symptoms, negative symptoms are qualities which are lacking in a person having a schizophrenic episode when compared to 'healthy' episodes; these include poverty of speech, impoverished ability to express emotion, lack of motivation, and apathy. </P>
<P>Treating these negative symptoms is a critical problem in the care of those with schizophrenia. New generation antipsychotics such as amisulpride, olanzapine and risperidone seem to have changed this slightly (<LINK REF="REF-Duggan-2002" TYPE="REFERENCE">Duggan 2002</LINK>, <LINK REF="REF-Kennedy-2002" TYPE="REFERENCE">Kennedy 2002</LINK>, <LINK REF="REF-Mota-Neto-2002" TYPE="REFERENCE">Mota Neto 2002</LINK>), but it remains unclear as to whether the effect of new generation antipsychotics relates to primary or only to secondary negative symptoms. 'Primary negative symptoms' in schizophrenia reflect a primary neural abnormality, whereas 'secondary negative symptoms' are induced by other factors (<LINK REF="REF-Flaum-1995" TYPE="REFERENCE">Flaum 1995</LINK>, <LINK REF="REF-Fleischhacker-2000" TYPE="REFERENCE">Fleischhacker 2000</LINK>). For example, if patients are distressed by medication side effects such as drug-induced akinesia or sedation, these side-effects can mimic negative symptoms, or patients who are suffering from positive symptoms such as delusions or hallucinations may avoid social contact and such behaviour can look like classic negative symptoms (social withdrawal), but it is secondarily induced by positive symptoms. Although we are not aware of clear epidemiological numbers, many patients continue to suffer from negative symptoms once the positive symptoms of schizophrenia have been effectively treated; this state is called 'residual schizophrenia' (<LINK REF="REF-Dilling-2000" TYPE="REFERENCE">Dilling 2000</LINK>). </P>
<P>Since antidepressants seem to have activating properties (<LINK REF="REF-Benkert-2003" TYPE="REFERENCE">Benkert 2003</LINK>), the addition of these drugs to antipsychotics is often used to treat negative symptoms. Certain guidelines such as the Texas Implementation of Medication Algorithm (TIMA) or the German national psychiatric association, recommend an add-on trial with antidepressants for patients who partially responded to antipsychotic medication and still have residual problems in the depressive or negative symptom spectrum (<LINK REF="REF-DGPPN-1998" TYPE="REFERENCE">DGPPN 1998</LINK>, <LINK REF="REF-Miller-2000" TYPE="REFERENCE">Miller 2000</LINK>). Potential concerns regarding combinations of antipsychotics and antidepressants include an increased side effect burden, possible unwanted pharmacodynamic and pharmacokinetic interactions, and consequently increased rates of non-compliance and cost. We therefore reviewed the evidence base for the efficacy and safety of antipsychotic and antidepressant combinations in the treatment of the negative symptoms of schizophrenia.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine whether: <BR/>1. Treatment with antipsychotic and antidepressant combinations is effective for those with schizophrenia and negative symptoms; and <BR/>2. Treatment with antipsychotic and antidepressant combinations is safe for the same illness.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-22 15:09:36 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-22 15:08:22 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials. Where a trial was described as 'double-blind', but it was only implied that the study was randomised, these trials were included in a sensitivity analysis. If there was no substantive difference within primary outcomes (see types of outcome measures) when these 'implied randomisation' studies were added, then they were included in the final analysis. If there was a substantive difference, only clearly randomised trials were used and the results of the sensitivity analysis described in the text. Quasi-randomised studies, such as those allocating by using alternate days of the week, were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia and pronounced negative symptoms as defined and diagnosed by the authors of the original studies. We also considered schizophrenia-like disorders such as schizophreniform psychoses, delusional disorder and schizoaffective psychoses for this review as long as the participants had pronounced negative symptoms. </P>
<P>For the feasibility of this review we widened the latter definition and accepted studies focusing on people with 'pronounced' negative symptoms as long as the study authors described that, for inclusion within the studies, people had to have presented with pronounced negative symptoms.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Treatment with antipsychotic and antidepressant medication: any dose and route of administration. </P>
<P>2. Treatment with antipsychotic medication only or with antipsychotic medication and placebo: any dose and route of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-22 15:08:22 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped all outcomes according to time - short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-22 15:07:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical response<BR/>1.1 No clinically significant response on negative symptoms - as defined by each of the studies<BR/>1.2 Average score/change in negative symptoms</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-22 15:08:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Leaving the study early</P>
<P>2. Service utilisation<BR/>2.1 Hospital admission<BR/>2.2 Days in hospital<BR/>2.3 Change in hospital status</P>
<P>3. Clinical response<BR/>3.1 No clinically significant response - as defined by each of the studies<BR/>3.2 No clinically significant improvement of global state<BR/>3.3 Average score/change in global state<BR/>3.4 Relapse - as defined by each of the studies<BR/>3.5 No clinically significant improvement in mental state - as defined by each of the studies<BR/>3.6 Average score/change in mental state<BR/>3.7 No clinically significant response on positive symptoms - as defined by each of the studies<BR/>3.8 Average score/change in positive symptoms<BR/>3.9 No clinically significant response on depressive symptoms - as defined by each of the studies<BR/>3.10 Average score/change in depressive symptoms<BR/>3.11 No clinically significant response on manic symptoms - as defined by each of the studies<BR/>3.12 Average score/change in manic symptoms<BR/>3.13 No clinically significant response on anxiety symptoms - as defined by each of the studies<BR/>3.14 Average score/change in anxiety symptoms<BR/>3.15 No clinically significant response on aggression/agitation symptoms - as defined by each of the studies<BR/>3.16 Average score/change in aggression/agitation symptoms</P>
<P>4. Behaviour<BR/>4.1 General behaviour<BR/>4.2 Specific behaviours<BR/>4.2.1 Social functioning<BR/>4.2.2 Employment status during trial (employed / unemployed)<BR/>4.2.3 Occurrence of incidents of violence (to self, others, or property)<BR/>4.2.4 Level of substance abuse</P>
<P>5. Adverse events<BR/>5.1 General adverse events<BR/>5.2 Specific adverse events<BR/>5.2.1 Allergic reactions<BR/>5.2.2 Blood dyscrasia such as agranulocytosis<BR/>5.2.3 Central nervous system (ataxia, nystagmus, drowsiness, fits, diplopia, tremor)<BR/>5.2.4 Death (suicide and non-suicide deaths)<BR/>5.2.5 Endocrinological dysfunction (hyperprolactinemia, disturbance of reproductive organ and sexual performance functioning)<BR/>5.2.6 Gastrointestinal (nausea, vomiting, diarrhoea)<BR/>5.2.7 Kidney dysfunction<BR/>5.2.8 Movement disorders (extrapyramidal side effects, including neuroleptic malignant syndrome and tardive dyskinesia)</P>
<P>6. Additional drug use<BR/>6.1 Antiparkinsonian medications<BR/>6.2 Benzodiazepines<BR/>6.3 Mood stabilizers</P>
<P>7. Quality of life</P>
<P>8. Economic burden (cost of care)</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-22 15:09:36 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-10-22 15:09:27 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group's Register (January 2004). This register is compiled by methodical searches of BIOSIS, CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile and is supplemented with hand searching of relevant journals and numerous conference proceedings.</P>
<P>The following phrases were used: [((*antidepress* or *triptylin* or *ipramin* or *ameser* or *amineptin* or *amoxapin* or *benactyzin* or *brofaromin* or *bupropion* or *caroxazon* or *cianopramin* or *citalopram* or *clorgyline* or *clovoxamine* or *danitracen* or*dapiprazole* or *demexiptilin* or deximafen* or dexamisole* or *dibenzepin* or *dimetacrin* or *dimenthazan* or *dioxadrol* or *dosulepin* or *dothiepin* or *doxepin* or *duloxetin* or *escitalopram* or *etoperidon* or *femoxetin* or *fenmetazol* or *fezolamin or *fluoxetin* or *flupent* or *fluvoxamin* or *gamfexin* or *ifoxetin* or *iprindol* or *iproniazid* or *isocarboxazid* or *levoprotiline* or *litracen* or *lofepramin* or *maprotilin* or *medifoxamin* or *melitracen* or *metapramin* or *mians* or *milnacipran* or *minaprin* or *mirtzapin* or *moclobemid* or *nefazodon* or *nialamid* or *nomeldin* or *nomifensin* or *opipramol* or *oxaflozan* or *oxaprotilin* or *oxitriptan* or *paroxetin* or *phenelzin* or *piberbalin* or *pipofezin* or *pirlindol* or *prazepin* or *praziton* or *propizepin* or *pridefin* or *quinupramine* or *reboxetin* or *rolipram* or *rubidium* or *sertralin* or *setiptilin* or *sibutramin* or *sodium hexacyclonate* or *teniloxazin* or *tianepin* or *tofenacin* or *toloxatone* or *trametralin* or *tranycypromin* or *trazium esilate* or *trazodon* or *trebenzomin* or *trocimine* or *tryptophan* or *venlafaxin* or *viloxazin* or *viqualin* or *zimeldin*) in REFERENCE) and ((antidep* or *triptylin* or *ipramin* or *oxetin* or *azadon* or amineptin* or bupropion* or citalopram* or doxepin* or flupent* or fluvoxamin* or gamfexin* or iproniazid* or isocarboxazid* or maprotilin* or mians* or minaprin* or mirtzapin* or moclobemid* or nialamid* or nomifensin* or rubidium* or sertralin* or tranycypromin* or tryptophan* or viloxazin*) in STUDY)].</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-22 15:09:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Reference lists<BR/>We searched all references of articles selected for inclusion for further relevant trials.</P>
<P>2. Personal contact<BR/>We contacted the first author of each included study for information regarding unpublished trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>[For definitions of terms used in this and other sections, please refer to the Glossary] </P>
<P>1. Study selection <BR/>We (CR, SL) independently inspected all citations of studies identified by the search. Where disagreement occurred we resolved this with WK, or, where any doubt remained, obtained the full article for further inspection. We then independently inspected these articles to assess their relevance to this review. Again, if the disagreement could not be resolved from published information, we added the article to the list of those awaiting assessment and contacted the authors of the study for clarification.</P>
<P>2. Quality assessment <BR/>We assessed the methodological quality of the trials included in this review using the criteria described in the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). This simple set of criteria is based on the evidence of a strong association between overestimation of effect and poor concealment of allocation (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and is defined as follows:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>For the purpose of the analysis in this review, trials were included if they meet criterion A or B of the Handbook. We gave trials not described as randomised by the authors a C rating and excluded them.</P>
<P>3. Data extraction <BR/>We (CR, SL) independently extracted data from selected trials. Where disagreement occurred, we attempted resolution by discussion. If doubt remained and further information was necessary to resolve the dilemma, we did not enter the data, but contacted the authors of the studies for further clarification. We documented reasons for excluding references from the review. </P>
<P>4. Data management<BR/>4.1 Intention to treat<BR/>For studies that did not specify the reasons for people leaving the study early (dropping out), we assumed them to have no change in the clinical outcome variables. A problem with increasing drop-out rates in randomised trials on drug treatment for schizophrenia has been reported (<LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK>). Since there is no evidence regarding what degree of attrition renders data analysis impossible, all trials were included in the main analysis. However, it was tested in a sensitivity analysis whether the exclusion of trials with drop-out rates higher than 50% significantly changed the results of the primary outcome parameters. When insufficient data were provided to identify the original group size (prior to drop-outs), we contacted the authors and added the trials to the list of those awaiting assessment. </P>
<P>4.2 Crossover design<BR/>We expected that some trials would use a crossover design. In order to exclude the potential additive effect on these trials in any further stages, we only analysed data from the first stage.</P>
<P>4.3 Data types<BR/>Outcomes are assessed using continuous measures (for example changes on a behaviour scale), categorical measures (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently RevMan does not support categorical data, so they could not be analysed as such.</P>
<P>4.3.1 Dichotomous data: Where possible, efforts were made to convert outcome measures to dichotomous data. This may be done by identifying cut off points on rating scales and dividing subjects accordingly into 'clinically improved' or 'not clinically improved'. If the authors of a study had used a predefined cut off point for determining clinical effectiveness we used this where appropriate. Otherwise we generally assumed that a 50% reduction of a scale (e.g. the Brief Psychiatric Rating Scale - <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or a rating of 'at least much improved' according to the Clinical Global Impression Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) could be considered as a clinically significant response. </P>
<P>For dichotomous outcomes, we estimated a relative risk (RR) with the 95% confidence interval (CI) based on a random effects model. When overall results were significant we calculated the number needed to treat (NNT) and/or the number needed to harm (NNH) as the inverse of the absolute risk reduction. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the effect.</P>
<P>4.3.2 Continuous data<BR/>4.3.2.1 Normal distribution: Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to data derived from continuous measures of endpoint ('state' data). The criteria were used before inclusion:<BR/>When a scale starts from zero, the standard deviation, when multiplied by two, is less than the mean (as the mean is otherwise unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite starting and end point and this rule can be applied. </P>
<P>When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale) it is impossible to tell whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale endpoint data, which typically cannot have negative values. If endpoint data were not available, the reviewers chose to use change data, because the statistics used in Metaview are rather robust with regard to skew. If a scale starts from a positive value (such as PANSS, which can have values from 30-210) the calculation described above in (b) should be modified to take the starting point of the scale into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.</P>
<P>4.3.2.2 Intention-to-treat versus completer analyses: in the case of continuous data it was assumed that in many cases an intention-to-treat analysis would not be available. For this reason we had to analyse the data as they were presented in the original publications. </P>
<P>4.3.2.3 Summary statistics: for continuous outcomes, we estimated a weighted mean difference (WMD) between groups. Again, we used a random effects model. Whenever possible we took the opportunity to make direct comparisons between trials that used the same measurement instrument to quantify specific outcomes. Where continuous data were presented from different scales rating the same effect, the data were summarized, calculating a standardized mean difference (SMD).</P>
<P>4.3.2.4 Rating scales: a wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or are even ad hoc. Some minimum standards must be set for outcome instruments. We only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), the instrument was either a self report or completed by an independent rater or relative (not the therapist), and the instrument could be considered as a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the raters, we commented on the data with the label 'prone to bias'. </P>
<P>4.4 Data display<BR/>We entered data into RevMan in such a way that the area to the left of the line of no effect indicated a favourable outcome for the antidepressant/antipsychotic combination group.</P>
<P>4.5 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). </P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>5. Heterogeneity<BR/>Firstly, we considered all of the included studies within any comparison to judge clinical heterogeneity. Then we visually inspected graphs used to investigate the possibility of statistical heterogeneity and supplemented this by using, primarily, the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If inconsistency was high, we did not summate the data, but presented it separately and investigated reasons for heterogeneity. </P>
<P>6. Publication bias <BR/>We entered data from all included trials into a funnel graph (trial effect versus trial size or 'precision') in an attempt to investigate the likelihood of overt publication bias. We did not undertake a formal test of funnel plot asymmetry (suggesting potential publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>)).</P>
<P>7. Sensitivity analysis<BR/>We examined in a sensitivity analysis whether the exclusion of trials with attrition rates higher than 50% led to a significant change in the results.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Please also see Tables of included and excluded studies.</P>
<P>1. Excluded studies<BR/>We excluded 112 studies. Reasons for exclusion were that the studies did not include people with pronounced negative symptoms (n=30), included people with schizophrenia and depressive symptoms (n=29), did not fulfil the predefined intervention criteria 'antipsychotic plus antidepressant' versus 'antipsychotic plus placebo' (n=27), included people with negative and/or positive symptoms (n=11), did not randomise adequately or at all (n=8), or included medications never marketed (n=5). Finally, some studies had no useable data (n=2).</P>
<P>2. Studies awaiting assessment <BR/>We are looking forward to receiving data from one trial adding fluoxetine to haloperidol treatment in schizophrenia (<LINK REF="STD-Lee-1997" TYPE="STUDY">Lee 1997</LINK>), but have not yet received an answer to our letter to the first author.</P>
<P>3. Ongoing and planned studies<BR/>We did not identify any ongoing or planned studies.</P>
<P>4. Included studies<BR/>We identified five studies for inclusion in this review.</P>
<P>4.1 Study design<BR/>All studies used a parallel group design.</P>
<P>4.2 Length of trials<BR/>All of the five studies were short term trials: <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> (5 weeks), <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> (7 weeks), <LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK> (12 weeks), <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> (12 weeks) and <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> (12 weeks). </P>
<P>4.3 Participants<BR/>Five studies provided usable data and included a total of 190 people (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK> - 58 participants, <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> - 39 participants, <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> - 29 participants, <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> - 30 participants and <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> - 34 participants). Participants were diagnosed with schizophrenia according to DSM-III R (<LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK>, <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK>) and DSM-IV (<LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK>, <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK>); the oldest study (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>), did not mention diagnostic criteria for schizophrenia. All studies examined patients with pronounced negative symptoms although they used different criteria for defining this. <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> used 'DSM-III-R criteria for chronic schizophrenia plus a score of at least "moderate" on one of the five global scales of the SANS. <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> used similar criteria plus a HAM-D baseline score of lower than 20 in order to exclude a major depressive episode. Hayashi 1997's definition was a DSM-IV diagnosis of schizophrenia plus moderate to severe negative symptoms in the PANSS while <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> used the DSM-IV diagnosis of chronic schizophrenia with at least 20 points on the negative subscale of the PANSS, at least a score of 4 on the CGI and a HAM-D score lower than 12. </P>
<P>4.4. Interventions<BR/>
<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK> compared perphenazine and amitriyptyline with perphenazine and placebo. In <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> participants continued with their previous antipsychotic medication and the addition of mianserin was compared with the addition of placebo. <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> continued previous antipsychotic medication and compared the addition of paroxetine 30 mg/d with the addition of placebo. <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> continued previous antipsychotic medication and added fluvoxamine or placebo. <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> compared the addition of fluoxetine 20 mg/d with the addition of placebo to the previous antipsychotic treatment, which was continued during the study period. <BR/> <BR/>4.5 Outcomes<BR/>A variety of scales were used to assess clinical response and adverse events although trialists also reported some non-scale-derived binary outcomes. </P>
<P>4.5.1 Outcome scales: details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are listed under "outcomes" in the "included studies" table.</P>
<P>4.5.1.1 Global functioning<BR/>Clinical Global Impression - CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used, with low scores indicating decreased severity and/or greater recovery.</P>
<P>4.5.1.2 Mental state<BR/>Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) <BR/>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 18 items, and each item can be rated on a seven-point scale varying from "not present" (1) to "extremely severe" (7). Scoring goes from 18 to 126.</P>
<P>Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>A 30-item schizophrenia scale which is subdivided into three subscales for measuring the severity of general psychopathology, positive symptoms, and negative symptoms. Each item can be rated on a seven-point scoring system varying from absent (1) to severe (7). Scoring goes from 30 to 210. Lower scores indicate lesser severity. </P>
<P>Hamilton Rating Scale for Depression - HAM-D (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>)<BR/>The HAM-D is a well-established 17-item scale for the measurement of depression and is sensitive to change.</P>
<P>Scale for the Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>)<BR/>A six-point (0-5) scoring system can be used for each global rating of alogia, affective blunting, avolition-apathy, anhedonia-asociality, and attention impairment. A low score indicates low levels of psychotic symptoms.</P>
<P>Wing Rating Scale (<LINK REF="REF-Wing-1961" TYPE="REFERENCE">Wing 1961</LINK>)<BR/>This scale consists of two parts. The first rates four typical symptoms of the schizophrenic mental state, based on a brief psychiatric interview, on a 5-point scale. The second is a 12-item behavioural schedule that rates on a three-point scale. The more acute the patient's condition, the higher the score on this scale.</P>
<P>4.5.1.3 Adverse events<BR/>No scales for adverse events provided usable data. Reasons for exclusion of data are listed under "outcomes" in the "included studies" table.</P>
<P>4.5.2 Missing outcomes<BR/>Because all of the studies for which data were available were short term studies, we know nothing about the medium and long term outcomes for this group of people.<BR/>There are no data on important outcomes such as service utilisation outcomes (admission to the hospital, days in the hospital, change in hospital status), behaviour (compliance with treatment), social functioning, economic outcomes, quality of life and cognitive functioning in either of the included studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>The included studies were reported as randomised, but trialists did not describe the means of randomisation, so all studies were allocated to category 'B'. </P>
<P>2. Blinding<BR/>All studies were double-blind, although none gave assurances that blinding was maintained. </P>
<P>3. Follow up<BR/>Only one study (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK>) provided unclear information on loss to follow up. <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK>, <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> and <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> indicated the number of participants who left the study early and the reason for leaving. <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> reported the total number of participants leaving the study early, but reasons for leaving were not provided. </P>
<P>4. Jaded scores<BR/>All studies achieved a Jaded score of three (the top Jaded score is five).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search<BR/>The search strategy identified 432 citations. Of these, 139 articles were ordered and inspected. We were ultimately able to include only five studies.</P>
<P>2. COMPARISON 1: ANTIPSYCHOTICS PLUS ANTIDEPRESSANTS VERSUS ANTIPSYCHOTICS PLUS PLACEBO</P>
<P>2.1 Leaving the study early<BR/>Overall results were equivocal with no significant difference between the combination of antipsychotics and antidepressants and the control group in terms of leaving the study early for any reason (n=90, 3 RCTs, RR 3.0 CI 0.35 to 26.04). Again, when it came to leaving specifically due to adverse events, two studies (<LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> and <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK>) found no significant difference between treatment groups (n=64, 2 RCTs, RR 5.0 CI 0.26 to 97.0). <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> also reports no difference in the number of participants leaving early due to inefficacy (n=34, 1 RCT, RR 3.0 CI 0.13 to 68.84). </P>
<P>2.2 Clinical response<BR/>Only <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> provided data from the Clinical Global Impression Scale (improvement and severity). Participants treated with antipsychotic and antidepressant medication had a statistically significantly greater improvement in global state (n=30, 1 RCT, WMD -1.0 CI -1.61 to -0.39) and had a significantly lower severity at endpoint (n=30, 1 RCT, WMD -0.9 CI -1.55 to -0.25) than those treated with antipsychotics and placebo.</P>
<P>2.3 Mental state<BR/>2.3.1 General<BR/>
<LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> and <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> provided data for BPRS total endpoint scores. No statistically significant difference in scores were found between treatment groups (n=60, 2 RCTs, WMD -4.89 CI -13.27 to 3.50). Although data were heterogeneous, no reasons could be identified and we considered the heterogeneity to be due to chance. <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> also found no significant difference in average score change on the BPRS (n=26, 1 RCT, WMD 0.1 CI -3.81 to 4.01).<BR/>
<BR/>2.3.2 Positive symptoms<BR/>Four studies presented data for the effects on positive symptoms but only <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> and <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> presented usable data. Data from <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> and <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> were skewed. <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> found no overall effect on the BPRS positive subscale (average change, n=26, 1 RCT, WMD 0.30 CI -3.61 to 4.21). <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> also found no overall effect on the PANSS positive subscale average change score. </P>
<P>2.3.3 Negative symptoms<BR/>2.3.3.1 Clinically significant improvement<BR/>
<LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> defined 'clinically significant improvement of negative symptoms' as a 20% or more decrease in SANS total score at endpoint compared to baseline and <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> used a 30% or more reduction on the same scale for their definition. <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> found that significantly more participants receiving adjunct antidepressants had a clinically significant improvement in negative symptoms compared with the antipsychotic plus placebo group (n=34, 1 RCT, RR 0.41 CI 0.23 to 0.73, NNT 2 CI 1 to 3). <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> yielded similar, favourable results (n=26, 1 RCT, RR 0.69 CI 0.48 to 0.99, NNT 3 CI 2 to 25). The result still significantly favours antidepressants when the two studies are combined (n=60, 2 RCTs RR 0.56 CI 0.32 to 0.97, NNT 3 CI 3 to 34).</P>
<P>2.3.3.2 Total endpoint scores<BR/>
<LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> used the PANSS and results between groups were equivocal (n=25, 1 RCT, WMD -2.27 CI -7.10 to 2.56). <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> and <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK>, however, found those in the treatment groups had significantly lower SANS scores than the control group (n=60, 2 RCTs, WMD -13.92 CI -19.93 to -7.92). </P>
<P>2.3.3.3 Average change in total scores<BR/>
<LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> presented SANS data and found no statistically significant difference between groups (n=26, 1 RCT, WMD -4.60 CI -11.10 to 1.90).</P>
<P>2.3.3.4 Various average endpoint scores<BR/>Using the SANS, data on different aspects of negative symptoms were reported by <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> and <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK>. <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> found those receiving adjunct antidepressants had a statistically significant lower score for 'affective flattening' than those in the control group (n=30, 1 RCT, WMD -7.0 CI -10.37 to -3.63) and a similar result for 'avolition' (n=30, 1 RCT, WMD -3.0 CI -5.04 to -0.96). Both <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> and <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> presented 'anhedonia' subscores but found no statistically significant difference between groups, although p-value could be regarded as borderline (n=60, 2 RCTs, WMD -2.58 CI -5.42 to 0.27). <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> also presented scores for 'attention' and again results were equivocal (n=30, 1 RCT, WMD -0.50 CI -2.28 to 1.28).</P>
<P>2.3.3.5 Various average change scores<BR/>
<LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> presented change data on these different aspects of negative symptoms. Affective flattening appeared to be better in those receiving antidepressants but the difference was borderline and not statistically significant (n=26, 1 RCT, WMD -2.80 CI -5.92 to 0.32). The average change of the 'alogia' subscores was, however, statistically different and favoured the treatment group (n=26, 1 RCT, WMD -3.0 CI -5.14 to -0.86). No difference in scores were found for avolition (n=26, 1 RCT, WMD 0.1 CI -2.02 to 2.22), anhedonia (n=26, 1 RCT, WMD -3.0 CI -1.97 to 1.37) or attention (n=26, 1 RCT, WMD 0.30 CI -1.65 to 2.25).</P>
<P>2.3.4 Depression<BR/>One study, <LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK>, presented usable data on depressive symptoms. Total endpoint scores on the HAM-D were significantly lower in the antipsychotic plus antidepressant group (n=30, 1 RCT, WMD -3.0 CI -5.54 to -0.46).</P>
<P>2.4 Behaviour<BR/>
<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK> used the Wing Scale to assess behaviour. Social withdrawal average change scores did not differ significantly between the two treatment groups (n=58, 1 RCT, WMD -0.93 CI -2.33 to 0.47). 'Socially embarrassing behaviour' was, however, affected by use of antidepressants. The average change scores were significantly different and favoured the treatment group (n=58, 1 RCT, WMD -0.90 CI -1.59 to -0.21).</P>
<P>2.5 Adverse events<BR/>3.5.1 General<BR/>Two studies (<LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK> and <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK>) found no statistically significant difference between treatment groups in regards to the outcome 'at least one adverse event' (n=84, 2 RCTs, RR 1.8 CI 0.66 to 4.90).</P>
<P>2.5.2 Specific - movement disorders<BR/>There were several measures of movement disorder, none showed any statistically significant difference: 'any extrapyramidal adverse event' (n=60, 2 RCTs, RR 5.0 CI 0.26 to 97.00), 'akathisia' (n=34, 1 RCT, RR 3.0 CI 0.13 to 68.84), 'parkinsonism' (n=92, 2 RCTs, RR 0.94 CI 0.21 to 4.24) and 'tremor' (n=34, 1 RCT, RR 3.00 CI 0.13 to 68.84).</P>
<P>2.5.3. Specific - other adverse events<BR/>No statistically significant differences were found for the two other adverse effects reported, 'dizziness' (n=26, 1 RCT, RR 3.00 CI 0.13 to 67.51) and 'somnolence' (n=26, 1 RCTs, RR 5.00 CI 0.26 to 95.02).</P>
<P>2.6. Additional drug use<BR/>Two studies (<LINK REF="STD-Spina-1994" TYPE="STUDY">Spina 1994</LINK> and <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK>) continued anticholinergic medication when present prior to study entry, but these studies did not indicate the number of patients actually receiving anticholinergics. In the <LINK REF="STD-Silver-1992" TYPE="STUDY">Silver 1992</LINK> study, all participants received anticholinergics; in the <LINK REF="STD-Collins-1967" TYPE="STUDY">Collins 1967</LINK> study, no participant received anticholinergics while in <LINK REF="STD-Jockers-2005" TYPE="STUDY">Jockers 2005</LINK> the use of anticholinergics remains unclear.</P>
<P>2.7 Publication bias<BR/>Entering data from all included trials into a funnel plot was not deemed reasonable due to the small number of included studies. </P>
<P>2.8 Sensitivity analysis<BR/>No trial had to be excluded due to attrition rates higher than 50%; therefore no sensitivity analysis was done.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. General<BR/>It is a common clinical strategy to use adjunctive antidepressant treatment for persisting negative symptoms; SSRIs were reported directly after investigational substances such as glycine as adjunctive treatment for persisting negative symptoms in recent guidelines (<LINK REF="REF-Kane-2003" TYPE="REFERENCE">Kane 2003</LINK>). Although over 400 citations were identified, it was possible to include only five studies with 219 participants into this review. This is a small base upon which to judge the effects of any additional drug treatment for patients with predominant negative symptoms of schizophrenia. No firm conclusions can be drawn on the efficacy and tolerability of antipsychotic and antidepressant combination. Therefore, further studies on antipsychotic and antidepressant combinations are needed and should use the newer antidepressants commonly in use today, such as selective serotonin reuptake inhibitors or serotonin and noradrenalin reuptake inhibitors. </P>
<P>2. Definitions for patients with pronounced/predominant negative symptoms<BR/>For this review, many studies had to be excluded because they did not study the appropriate participants. For example patients with both, negative and positive symptoms or patients with negative symptoms and major depressive episodes. In such patients it is unclear whether an effect on the negative symptoms is not just secondary to the reduction of depression or of positive symptoms. As the <LINK REF="STD-Hayashi-1997" TYPE="STUDY">Hayashi 1997</LINK> study appeared to be the weakest in terms of inclusion criteria, because depressive symptoms were only weakly controlled for, we undertook a sensitivity analysis to see whether its exclusion would change the overall results, but the effect of antidepressants on negative symptoms remained (n=85, 3 RCTs, SMD -0.90 CI -1.45 to -0.35).</P>
<P>A further problem was the definition of negative symptoms. Different definitions of negative symptoms have been proposed in the past. Most of them include the three categories 'affective flattening', 'anhedonia/anergia' and 'cognitive impairment', although it has been argued that only affective flattening can be seen as a core negative symptom showing no correlation with depressive symptoms (<LINK REF="REF-M_x00f6_ller-1994" TYPE="REFERENCE">Möller 1994</LINK>). </P>
<P>In the included studies, negative symptoms were defined very differently; definitions ranged from 'anergic, withdrawn, inactive long-term schizophrenic patients' in the older studies to 'having at least a minimum score on the Scale for the Assessment of Negative Symptoms plus having not more than a certain maximum score in the Hamilton Depression Rating Scale'. The latter definition appears to be reasonable for studying patients with negative symptoms to ensure that patients are not depressed; in addition, it would be justified to exclude patients with pronounced positive symptoms and clear extrapyramidal side effects as these might cause secondary negative symptoms. </P>
<P>3. Comparison 1: Antipsychotic plus antidepressant versus antipsychotic plus placebo</P>
<P>3.1 Leaving the study early<BR/>There was no significant difference in regard to leaving the study early between the two treatment groups. This can be interpreted as indicating a comparable acceptability of both treatment groups. </P>
<P>3.2 Global state<BR/>One study indicated data on CGI and showed a statistically significantly greater improvement and a significantly lower severity at endpoint on the CGI in the group treated with antipsychotic and antidepressant medications. However, these data derive from one short term study only. More data, especially for the medium and long term, may yield more information.</P>
<P>3.3 Mental state<BR/>The results on mental state suggest that adding antidepressants to antipsychotics can improve negative symptoms in schizophrenia, or at least certain aspects of negative symptoms such as 'affective flattening', 'alogia' and 'avolition'. However, more data are needed to confirm these findings.</P>
<P>3.4 Adverse events<BR/>Four studies provided usable data on adverse events, none of the reported adverse events showed any statistically significant difference between the treatment groups. Again, the data are too limited to allow any firm conclusion to be drawn.</P>
<P>3.5. Missing outcomes<BR/>Data on medium or long-term outcomes, service utilisation, compliance with treatment, social functioning, economic outcomes, quality of life and cognitive functioning are absent.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-04-26 14:51:15 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE>
<P>1. For people with schizophrenia and pronounced negative symptoms<BR/>This review suggests that the combination of antidepressants with antipsychotics may be more effective in treating some negative symptoms of schizophrenia than antipsychotic treatment alone; but even for these outcomes the evidence base is small and more and larger studies are necessary. </P>
<P>2. For clinicians<BR/>Based on currently available randomised trial-derived evidence, the data are too limited to assess whether the addition of antidepressants to antipsychotics is particularly useful for persons with schizophrenia and pronounced negative symptoms. That antidepressants improve negative symptoms leading to higher quality of life, better social functioning, higher employment status etc. is, as yet, not proven. </P>
<P>3. For managers and policy makers<BR/>Managers and policy makers should be aware that the common clinical strategy of adding antidepressants to antipsychotics for those with pronounced negative symptoms in schizophrenia is not based on firm evidence derived from randomised controlled trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-04-26 14:51:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>Any future studies should respect standards of measuring outcomes and of reporting data in order to enhance the comparability of study results (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>, <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). In the included studies data reporting was poor; this further limited the impact of the few studies.</P>
<P>2. Specific<BR/>More relevant studies are needed. At least some of these should be independent of industry, as industry-sponsored studies are subject to substantial biases (<LINK REF="REF-Lexchin-2003" TYPE="REFERENCE">Lexchin 2003</LINK>, <LINK REF="REF-Healy-2003" TYPE="REFERENCE">Healy 2003</LINK>). For these studies the definition of negative symptoms and the discrimination of depressive symptoms should be standardized to enhance their comparability (<LINK REF="REF-M_x00f6_ller-1994" TYPE="REFERENCE">Möller 1994</LINK>). Well-designed, large, medium and long term, fully reported pragmatic trials with clinically relevant outcomes such as relapse, recurrence of negative symptoms and rehospitalisation are essential but lacking at this point. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for suggested study design.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank the editorial base of the CSG for their help.<BR/>This study is part of the German Research Network on Schizophrenia and was funded by the German Federal Ministry for Education and Research (grant 01 GI 993x).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>CR received lecture honoraria and/or travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, Eli Lilly and Pfizer. SL and WK received lecture honoraria and/or travel grants to attend scientific meetings from Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Novartis, Pfizer, Sanofi-Synthélabo and Zeneca. They also received financial support for a randomised trial from Eli Lilly, and for a meta-analysis on amisulpride from Sanofi-Synthélabo.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Christine Rummel: Protocol development, searching, data extraction, analysis, data interpretation and writing the final report.</P>
<P>Werner Kissling: Fund raising, protocol development, data interpretation.</P>
<P>Stefan Leucht: Fund raising, protocol development, searching, data extraction, data checking, data interpretation.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-22 15:25:05 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-1967" NAME="Collins 1967" YEAR="1967">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collins AD, Dundas J</AU>
<TI>A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1967</YR>
<VL>113</VL>
<PG>1425-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68103522"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4865295"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayashi-1997" NAME="Hayashi 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hayashi T, Yokota N, Takahashi T, Tawara Y, Nishikawa T, Yano T, Furutani M, Fujikawa T, Horiguchi J, Yamawaki S</AU>
<TI>Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>4</NO>
<PG>199-205</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98006929"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9347380"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yamawaki S, Hayashi T, Yokota N, Takahashi T, Sato G, Tahara Y</AU>
<TI>Serotonin-dopamine antagonists in elderly schizophrenics</TI>
<SO>Congress of the collegium internationale neuro-psychopharmacologicum 1996 Jun 23-27; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jockers-2005" NAME="Jockers 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jockers-Scherübl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P</AU>
<TI>Improvement of schizophrenic negative symptoms by the addition of paroxetine to antipsychotics: a double-blind placebo-controlled study</TI>
<SO>Poster presentation at the Winter Workshop on Schizophrenia, Davos 2004</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jockers-Scherübl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P</AU>
<TI>Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>20(1)</VL>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jockers-Scherübl MC, Godemann F, Bauer A, Wolfensteller U</AU>
<TI>Primary negative symptoms in schizophrenia: Treatment with paroxetine in a double-blind placebo-controlled trial</TI>
<SO>The Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Supplement 3</NO>
<PG>S325</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Hallo P.2.168"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-1992" NAME="Silver 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Nassar A</AU>
<TI>Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study</TI>
<SO>Biological Psychiatry</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>7</NO>
<PG>698-704</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92288061"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1599987"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spina-1994" NAME="Spina 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Spina E, de Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE, Caputi AP</AU>
<TI>Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>4</NO>
<PG>281-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95173375"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1994377866; PMID 7868850"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Addington-2002" NAME="Addington 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, Beauclair L</AU>
<TI>Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21657241"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11799338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addington DE, Addington J, Patten S, Remington GJ, Moamai J, Labelle A</AU>
<TI>Sertraline for depression in remitted schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1,2</NO>
<PG>219</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 2001-14485-009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anashkina-1990" NAME="Anashkina 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anashkina, L, M</AU>
<TI>Comparative effectiveness of various methods of the treatment of patients with attack-like SCHIZophrenia with depressive episodes</TI>
<TO>[data not available]</TO>
<SO>Zhurnal Nevropatologii I Psikhiatrii Imeni S. S. Korsakova</SO>
<YR>1990</YR>
<VL>90</VL>
<NO>7</NO>
<PG>90-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76278284"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 786317"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arango-2000" NAME="Arango 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arango C, Kirkpatrick B, Buchanan RW</AU>
<TI>Fluoxetine as an add on medication to typical antipsychotics in chronic schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>211</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69063781"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5726835"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arango C, Kirkpatrick B, Buchanan RW</AU>
<TI>Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>2000</YR>
<VL>188</VL>
<NO>1</NO>
<PG>50-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 2000-13334-009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arbitman-1970" NAME="Arbitman 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arbitman R, Yurtcu A, Lehmann HE, Sterlin C, Ban TA, Jarrold L</AU>
<TI>Protriptyline in the treatment of chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>3</NO>
<PG>131-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70155688"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4985491"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldini-1970" NAME="Baldini 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baldini JT, Neary ER</AU>
<TI>Controlled trials of an amitriptyline-fluphenazine combination in depressive neuroses and psychoses: a collaborative study</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>2</NO>
<PG>84-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70113586"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4984324"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barron-1964" NAME="Barron 1964" YEAR="1964">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barron A, Rudy LH, Smith JA</AU>
<TI>Clinical evaluation of a secondary amine, nortriptyline</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1964</YR>
<VL>121</VL>
<PG>268-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 69-06057"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1970" NAME="Becker 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Becker RE</AU>
<TI>Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1970</YR>
<VL>127</VL>
<NO>6</NO>
<PG>827-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71040635"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4921622"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1977" NAME="Becker 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Becker RE, Shaskan EG</AU>
<TI>Platelet monoamine oxidase activity in schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1977</YR>
<VL>134</VL>
<NO>5</NO>
<PG>512-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 59-03499"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1983" NAME="Becker 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Becker RE</AU>
<TI>Implications of the efficacy of thiothixene and a chlorpromazine-imipramine combination for depression in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1983</YR>
<VL>140</VL>
<PG>208-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83098039"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6336916"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berk-2001" NAME="Berk 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berk M, Ichim C, Brook S</AU>
<TI>Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>2</NO>
<PG>87-92</PG>
<PB>Lippincott Williams and Wilkins.</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21130800"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11236073; PsycINFO 2001-00102-003"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ichim C, Berk M, Brook S</AU>
<TI>Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S112</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="XXIInd C.I.N.P. [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P01078"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berman-1995" NAME="Berman 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berman I, Sapers BL, Chang HH, Losonczy MF, Green AI</AU>
<TI>Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>3</NO>
<PG>206-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00362390"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogetto-1995" NAME="Bogetto 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bogetto F, Fonzo V, Maina G, Ravizza L</AU>
<TI>Adjunctive fluoxetine or amisulpride improves schizophrenic negative symptoms</TI>
<SO>European Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>2</NO>
<PG>119-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70113586"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4984324"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brockington-1978" NAME="Brockington 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brockington IF, Kendell RE, Kellett JM, Curry SH, Wainwright S</AU>
<TI>Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1978</YR>
<VL>133</VL>
<PG>162-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78236310"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 354733"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchanan-1996" NAME="Buchanan 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A</AU>
<TI>Fluoxetine augmentation of clozapine treatment in patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>12</NO>
<PG>1625-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97097921"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 8942462"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-1961" NAME="Casey 1961" YEAR="1961">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM</AU>
<TI>Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1961</YR>
<VL>117</VL>
<PG>997-1003</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 74-32161"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Centorrino-1994" NAME="Centorrino 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG</AU>
<TI>Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<NO>1</NO>
<PG>123-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94091485"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 8267110"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1975" NAME="Chouinard 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L, Serrano M, Albert JM, Charette R</AU>
<TI>Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controlled study of drug interaction</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1975</YR>
<VL>32</VL>
<NO>10</NO>
<PG>1295-307</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76038906"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1101843"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L</AU>
<TI>Phenothiazine-induced ECG abnormalities: effect of a glucose load</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>8</NO>
<PG>951-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77241119"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 329786"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper SF, Dugal R, Elie R, Albert JM</AU>
<TI>Metabolic interaction between amitriptyline and perphenazine in psychiatric patients</TI>
<SO>Progress in Neuropsychopharmacology</SO>
<YR>1979</YR>
<VL>3</VL>
<NO>4</NO>
<PG>369-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="90047292"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 400992"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1977" NAME="Chouinard 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Annable L</AU>
<TI>The effect of rubidium in schizophrenia</TI>
<SO>Communications in Psychopharmacology</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>4</NO>
<PG>373-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78237939"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 61-01590; PMID 28202"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1979" NAME="Chouinard 1979" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Jones BD</AU>
<TI>Evidence of brain dopamine deficiency in schizophrenia</TI>
<SO>Canadian Journal of Psychiatry (Revue Canadienne de Psychiatrie)</SO>
<YR>1979</YR>
<VL>24</VL>
<NO>7</NO>
<PG>661-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1980059772"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claghorn-1967" NAME="Claghorn 1967" YEAR="1967">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Claghorn JL, Schoolar JC, Ryan JW, Kinross-Wright J</AU>
<TI>Combined therapy in chronic schizophrenics stabilized on phenothiazine tranquilizers and given BL-KR140 or imipramine or placebo concurrently</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1967</YR>
<VL>9</VL>
<NO>11</NO>
<PG>576-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68097606"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4965507"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1968" NAME="Clark 1968" YEAR="1968">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR</AU>
<TI>Evaluation of trifluperidol in chronic schizophrenia</TI>
<SO>Psychopharmacologia</SO>
<YR>1968</YR>
<VL>12</VL>
<NO>3</NO>
<PG>193-203</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70283839"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4917285"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-2000" NAME="Cooper 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cooper SJ, Mulholland C, Lynch G, Baynes D, King DJ</AU>
<TI>Sertraline in the treatment of depressive symptoms in stable, chronic schizophrenia: a placebo controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>209</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99422524"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 10492856"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crosse-1974" NAME="Crosse 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crosse B</AU>
<TI>Clinical trials of sulpiride (1403 RD - Dogmatil): Its advantages prescribed alone or in combination</TI>
<SO>Psychologie Medicale</SO>
<YR>1974</YR>
<VL>6</VL>
<NO>8</NO>
<PG>1623-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 57-03755"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1994" NAME="Daniel 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S, et al</AU>
<TI>Coadministration of fluvoxamine increases serum concentrations of haloperidol</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>5</NO>
<PG>340-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95105367"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7806690"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Decina-1994" NAME="Decina 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio PL</AU>
<TI>Adjunctive trazodone in the treatment of negative symptoms of schizophrenia</TI>
<SO>Hospital and Community Psychiatry</SO>
<YR>1994</YR>
<VL>45</VL>
<NO>12</NO>
<PG>1220-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1994372162"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Den-Boer-2000" NAME="Den Boer 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Den Boer JA, Vahlne J O, Post P, Heck AH, Daubenton F, Olbrich R</AU>
<TI>Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia</TI>
<SO>Human Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>3</NO>
<PG>179-89</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2000170004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deutsch-1977" NAME="Deutsch 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Deutsch M, Ban TA, Lehmann HE</AU>
<TI>A standard-controlled clinical study with trazodone in schizophrenic patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>13-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77234969"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 329321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dim-1968" NAME="Dim 1968" YEAR="1968">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dim BH, Kurland AA</AU>
<TI>Controlled study of BL-KR140 on chronic anergic schizophrenic patients stabilized with a neuroleptic compound</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1968</YR>
<VL>10</VL>
<NO>6</NO>
<PG>288-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68357056"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4969835"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dohner-1969" NAME="Dohner 1969" YEAR="1969">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dohner W, Eckmann F</AU>
<TI>Clinical studies with noxiptilin in long-term hospitalized schizophrenic patients</TI>
<TO>Klinische Untersuchungen mit Noxiptilin bei langjahrig hospitalisierten schizophrenen Kranken</TO>
<SO>Arzneimittel Forschung</SO>
<YR>1969</YR>
<VL>19</VL>
<NO>Suppl 5</NO>
<PG>S908-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69258826"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4895497"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dua-1990" NAME="Dua 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dua D, Agarwal AK, Dalal PK</AU>
<TI>Imipramine in schizophrenia with depressive symtomatology</TI>
<SO>Indian Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>32</VL>
<NO>3</NO>
<PG>229-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2000170004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dufresne-1988" NAME="Dufresne 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dufresne RL, Kass DJ, Becker RE</AU>
<TI>Bupopropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia</TI>
<SO>Drug Development Research</SO>
<YR>1988</YR>
<VL>12</VL>
<NO>3-4</NO>
<PG>259-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1988101137"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evins-2001" NAME="Evins 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC</AU>
<TI>A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2001</YR>
<VL>3</VL>
<PG>397-403</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21551576"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11694208"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fink-1963" NAME="Fink 1963" YEAR="1963">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fink M, Pollack M, Klein DF, Blumberg AG, Belmont I, Karp E, Kramer JC, Willner A</AU>
<TI>Comparative studies of chlorpromazine and imipramine. 1. Drug discriminating patterns</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1963</YR>
<VL>3</VL>
<PG>370-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75100387"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 54-07814; PMID 1113862"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1967" NAME="Gallant 1967" YEAR="1967">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM, Bishop MP, O'Meallie L</AU>
<TI>BL-KR140: a controlled evaluation in chronic schizophrenic patients previously stabilized on chlorpromazine</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1967</YR>
<VL>9</VL>
<NO>8</NO>
<PG>447-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67216347"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4962470"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-George-2002" NAME="George 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR</AU>
<TI>A placebo controlled trial of bupropion for smoking cessation in schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2002</YR>
<VL>52</VL>
<NO>1</NO>
<PG>53-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="BIOSIS 00424318"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-1995" NAME="Goff 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Midha KK, Sarid Segal O, Hubbard JW, Amico E</AU>
<TI>A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>117</VL>
<NO>4</NO>
<PG>417-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95327798"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7604142"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goncalves-1976" NAME="Goncalves 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goncalves N</AU>
<TI>Changes of behavior in a group of hospitalized chronic schizophrenics treated with EMD 16 139, a benzochinolizin derivative</TI>
<TO>Veranderung des Antriebs bei hospitalisierten chronisch Schizophrenen unter der Behandlung mit EMD 16 139, einem Benzochinolizinderivat</TO>
<SO>International Pharmacopsychiatry</SO>
<YR>1976</YR>
<VL>11</VL>
<NO>2</NO>
<PG>65-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76237143"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 939672; PsycINFO 57-03982"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goode-1983" NAME="Goode 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goode DJ, Manning AA</AU>
<TI>Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<NO>7</NO>
<PG>253-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83238233"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6408068"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haider-1966" NAME="Haider 1966" YEAR="1966">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haider I</AU>
<TI>A comparative trial of nortriptyline and amitriptyline in chronic schizophrenia</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1966</YR>
<VL>20</VL>
<NO>8</NO>
<PG>416-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66165897"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5329316"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2000" NAME="Han 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Han PJ, Paik YS, Oh SW, Jeon HT, Kim JY</AU>
<TI>The Effect of Paroxetine in Chronic Schizophrenic Inpatients with Depressive Symptoms: A Double-Blind Placebo-Controlled Study</TI>
<SO>Journal of Korean Neuropsychiatric Association</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>4</NO>
<PG>774-786</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="KoreaMED"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1964" NAME="Hanlon 1964" YEAR="1964">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Nussbaum K, Wittig B, Hanlon DD, Kurland AA</AU>
<TI>The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients</TI>
<SO>Journal of New Drugs</SO>
<YR>1964</YR>
<VL>4</VL>
<PG>52-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66165897"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5329316"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanlon-1975" NAME="Hanlon 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanlon TE, Blatchley RJ, Kurland AA</AU>
<TI>Effects of control techniques on therapeutic outcome in a controlled clinical trial</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1975</YR>
<VL>10</VL>
<NO>3</NO>
<PG>169-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76004972"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1099048"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogarty-1995" NAME="Hogarty 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J</AU>
<TI>Pharmacotherapy of impaired affect in recovering schizophrenic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>1</NO>
<PG>29-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95110214"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7811160"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jasovic_x002d_Gasic-1991" NAME="Jasovic-Gasic 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jasovic-Gasic M, Danic Z, Kunovac J</AU>
<TI>Efficacy of mianserni and amitriptyline in the treatment of depression in schizophrenia: Comparative study</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1991</YR>
<VL>15</VL>
<PG>249B</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00362469"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1981" NAME="Johnson 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DAW</AU>
<TI>A double-blind trial of nortriptyline for depression in chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>139</VL>
<NO>2</NO>
<PG>97-101</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1982028096"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasckow-2001" NAME="Kasckow 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kasckow JW, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste DV</AU>
<TI>Citalopram augmentation of antipsychotic treatment in older schizophrenia patients</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>1163-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21614961"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11748776"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirli-1998" NAME="Kirli 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kirli S, Caliskan M</AU>
<TI>A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>1-2</NO>
<PG>103-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98456689"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9783350"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1967" NAME="Klein 1967" YEAR="1967">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klein DF</AU>
<TI>Importance of psychiatric diagnosis in prediction of clinical drug effects</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1967</YR>
<VL>16</VL>
<NO>1</NO>
<PG>118-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67059711"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5333776"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein DF</AU>
<TI>Psychiatric diagnosis and a typology of clinical drug effects</TI>
<SO>Psychopharmacologia</SO>
<YR>1968</YR>
<VL>13</VL>
<NO>5</NO>
<PG>359-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69092555"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4884170"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1974" NAME="Klein 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klein RH, Lynn EJ, Axelrod H, Dluhy J</AU>
<TI>Self-administration of medication by psychiatric inpatients</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1974</YR>
<VL>158</VL>
<PG>450-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74271792"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4841291"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komori-1995" NAME="Komori 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Komori T</AU>
<TI>Clinical study of iminodibenzyl compound (Cremin(R)) on schizophrenic patients</TI>
<TO>[data not available]</TO>
<SO>Japanese Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>8</NO>
<PG>295-302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1995326200"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kondo-1975" NAME="Kondo 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kondo H, Imai H, Takahashi S</AU>
<TI>Comparison of the clinical efficacy of penfluridol and carpipramine for schizophrenia by the double-blind method</TI>
<TO>[data not available]</TO>
<SO>Seishin Igaku</SO>
<YR>1975</YR>
<VL>4</VL>
<NO>11</NO>
<PG>1373-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00267922; Cochrane Library JRCT 76W1962E012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kornhuber-1985" NAME="Kornhuber 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kornhuber HH, Lisson G, Rissotto R</AU>
<TI>Treatment of schizophrenia without symptoms with viloxazine</TI>
<TO>Behandlung der schizophrenen Minussymptomatik mit Viloxazin</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1985</YR>
<VL>110</VL>
<NO>17</NO>
<PG>698</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85179033"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 3886343"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kothari-1960" NAME="Kothari 1960" YEAR="1960">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kothari NJ, Saunders JC, Kline NS, Griffen JA</AU>
<TI>A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>117</VL>
<PG>358-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 74-08128"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1989" NAME="Kramer 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavicchia S, Little PSchmidt R, Kimes I</AU>
<TI>Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>10</NO>
<PG>922-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="90025673"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2679483"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurland-1966" NAME="Kurland 1966" YEAR="1966">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kurland AA, Bethon GD, Michaux MH, Agallianos DD</AU>
<TI>Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings</TI>
<SO>Journal of New Drugs</SO>
<YR>1966</YR>
<VL>6</VL>
<PG>80-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67014950"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5331284"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurland-1981" NAME="Kurland 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kurland AA, Nagaraju A</AU>
<TI>Viloxazine and the depressed schizophrenic - methodological issues</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1981</YR>
<VL>21</VL>
<NO>1</NO>
<PG>37-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81168674"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7012190"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapolla-1967" NAME="Lapolla 1967" YEAR="1967">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lapolla A</AU>
<TI>A double blind evaluation of chlorpromazine versus a combination of perphenazine and amitriptyline</TI>
<SO>International Journal of Neuropsychiatry</SO>
<YR>1967</YR>
<VL>3</VL>
<NO>5</NO>
<PG>403-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1968-07423-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lauriello-2001" NAME="Lauriello 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lauriello J, Bustillo J, Hammond R, Bogenshutz M, Keith SJ</AU>
<TI>Treatment of weight-gain with fluoxetine in olanzapine-treated schizophrenic outpatients</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2</NO>
<PG>236</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2003135648"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1998" NAME="Lee 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee MS, Kim YK, Lee SK, Suh KW</AU>
<TI>Sertraline as an adjunctive to neuroleptics in chronic schizophrenia</TI>
<SO>6th world congress of biological psychiatry; 1997 Jun 22-27; Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee MS, Kim YK, Lee SK, Suh KY</AU>
<TI>A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>5</NO>
<PG>399-403</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99004818"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9790158"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehmann-1970" NAME="Lehmann 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann, Ban</AU>
<TI>Doxepin in Schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1970</YR>
<VL>7</VL>
<NO>2</NO>
<PG>55-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="13035"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehmann-1977" NAME="Lehmann 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann HE, Ban TA</AU>
<TI>A placebo controlled clinical study with trazodone in schizophrenic patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>11-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77234968"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 329320"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maeda-1972" NAME="Maeda 1972" YEAR="1972">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maeda S, Tanaka M, Tanaka I</AU>
<TI>Comparison of the clinical efficacy of y-4153, carpipramine for schizophrenia and depression by the double-blind cross-over method</TI>
<SO>Shinryo to shinyaku</SO>
<YR>1972</YR>
<VL>9</VL>
<NO>12</NO>
<PG>24-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00267922; Cochrane Library JRCT 76W1962E012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masciocchi-1974" NAME="Masciocchi 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Masciocchi A, Reitano S, Vanini M, Cicchetti V</AU>
<TI>Preliminary results of a controlled trial with sulpiride versus chlorimipramine in chronic schizophrenic patients with marked ideo-emotional poverty</TI>
<TO>Risultati preliminari di una prova controllata con sulpiride versus clorimipramina in pazienti schizofrenici cronici con marcata sintomatologia deficitaria</TO>
<SO>Rivista di Patologia Nervosa e Mentale</SO>
<YR>1974</YR>
<VL>95</VL>
<PG>47-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75027787"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4421825"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michaux-1966" NAME="Michaux 1966" YEAR="1966">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Michaux MH, Kurland AA, Agallianos DD</AU>
<TI>Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1966</YR>
<VL>8</VL>
<PG>S117-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66111113"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4956162"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulholland-2003" NAME="Mulholland 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mulholland C, Lynch G, King DJ, Cooper SJ</AU>
<TI>A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>107-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2003135648"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1998" NAME="Muller 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muller Siecheneder F, Muller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O</AU>
<TI>Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>111-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98216434"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9555596; EMBASE 1998140818"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussbaum-1964" NAME="Nussbaum 1964" YEAR="1964">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nussbaum K, Shaffer JW, Michaux WW</AU>
<TI>Modaline sulfate in the treatment of chronic schizophrenics</TI>
<SO>Journal of New Drugs</SO>
<YR>1964</YR>
<VL>4</VL>
<NO>2</NO>
<PG>86-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1965-05331-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogata-1981" NAME="Ogata 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ogata H, Ogata F, Miyashita S, Yuki M</AU>
<TI>Experimental uses of iminodibenzyl derivatives in chronic schizophrenia. A double blind, cross-over test by using placebo</TI>
<TO>Essai de derives de l'iminodibenzyle dans la schizophrenie chronique. Etude par permutation a double insu contre placebo</TO>
<SO>Psychologie Medicale</SO>
<YR>1981</YR>
<VL>13</VL>
<NO>2</NO>
<PG>351-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74297328"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 53-05875; PMID 4603991; PMID 4603991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oltman-1966" NAME="Oltman 1966" YEAR="1966">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oltman JE, Friedman S</AU>
<TI>Perphenazine-amitriptyline in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1966</YR>
<VL>123</VL>
<NO>5</NO>
<PG>607-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67022351"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5331928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-1965" NAME="Park 1965" YEAR="1965">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Park LC, Baldessarini RJ, Kety SS</AU>
<TI>Methionine effects on chronic schizophrenics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1965</YR>
<VL>12</VL>
<PG>346-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83227210"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7183131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pishkin-1962" NAME="Pishkin 1962" YEAR="1962">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pishkin V</AU>
<TI>CPT and VCRT performances as functions of imipramine and nialamide</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1962</YR>
<VL>18</VL>
<NO>1</NO>
<PG>83-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1964-07575-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-2002" NAME="Potkin 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Thyrum PT, Alva G, Carreon D, Yeh C, Kalali A, Arvanitis LA, Pharmacokinetic Study Group</AU>
<TI>Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>174-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21906967"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 11910263"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poyurovsky-1999" NAME="Poyurovsky 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A</AU>
<TI>Treatment of neuroleptic induced akathisia with the 5 HT2 antagonist mianserin. Double blind, placebo controlled study</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>174</VL>
<PG>238-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99377558"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 10448449"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poyurovsky-2002" NAME="Poyurovsky 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poyurovsky M, Isaaks I, Pashnian A, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A</AU>
<TI>Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients</TI>
<SO>The Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Supplement 3</NO>
<PG>S312</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Hallo P.2.138"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A</AU>
<TI>Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>6</NO>
<PG>1058-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Poyurovsky M, Pashnian A, Fuchs C, Gilad I, Maayan R, Weizman A</AU>
<TI>Olanzapine-induced weight gain in patients with first-episode schizophrenia</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NR495 Wednesday, May 9, 12:00 p.m.-02:00 p.m"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poyurovsky-2003" NAME="Poyurovsky 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman RWA</AU>
<TI>Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<PG>297-302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="22449967"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 12562576"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poyurovsky-2003a" NAME="Poyurovsky 2003a" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A</AU>
<TI>Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: A double-blind randomized placebo-controlled pilot study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>305-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 2003273326"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prusoff-1979" NAME="Prusoff 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prusoff BA, Williams DH, Weissman MM, Astrachan BM</AU>
<TI>A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1979</YR>
<VL>36</VL>
<NO>2</NO>
<PG>80-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79158604"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 373008"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prusoff BA, Williams DH, Weissman MM, Astrachan BM</AU>
<TI>Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1979</YR>
<VL>15</VL>
<NO>5</NO>
<PG>569-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79164823"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 373665"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reinhardt-1959" NAME="Reinhardt 1959" YEAR="1959">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reinhardt RF, Schiff SB, Sinnett ER</AU>
<TI>The use of triflupromazine with iproniazid for the treatment of chronic schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1959</YR>
<VL>116</VL>
<PG>68-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="547447"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reznik-2000" NAME="Reznik 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reznik I, Sirota P, Psych M</AU>
<TI>Obsessive and compulsive symptoms in schizophrenia: A randomized controlled trial with fluvoxamine and neuroleptics</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>4</NO>
<PG>410-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20372069"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2000256070; PMID 10917401"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robak-1973" NAME="Robak 1973" YEAR="1973">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robak OH</AU>
<TI>Pipotiazine palmitate (19552 RP) in the long-term treatment of chronic psychoses. A controlled trial on in- patients</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1973</YR>
<VL>241</VL>
<PG>83-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74004712"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4147515"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosini-1989" NAME="Rosini 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosini E, Agnes M, D'Avossa G</AU>
<TI>Clinico-therapeutic considerations regarding "short- term psychosis" in African patients</TI>
<TO>Considerazioni clinico-terapeutiche sulla "psicosi reattiva breve" in pazienti africani</TO>
<SO>Psichiatria e Psicoterapia Analitica</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>2</NO>
<PG>169-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 28-76756"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salokangas-1996" NAME="Salokangas 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Salokangas RKR, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, Tuominen J, Ahola V, Syvalahti E</AU>
<TI>Citalopram as an adjuvant in chronic schizophrenia - a double-blind placebo-controlled study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1996</YR>
<VL>94</VL>
<NO>3</NO>
<PG>175-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97046161"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1996287726; PMID 8891083"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, Dahl ML, Salokangas RK</AU>
<TI>Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients</TI>
<SO>Journal of International Medical Research</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>1</NO>
<PG>24-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97179384"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9027670"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samejima-1972" NAME="Samejima 1972" YEAR="1972">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Samejima K, Inuzuka T, Uchimura H, ,</AU>
<TI>The clinical evaluation of y-4153, a new psychotropic drug: comparison of y-4253 and carpipramine for chronic schizophrenia by the double-blind method</TI>
<TO>[data not available]</TO>
<SO>Shinyakutorinsyo</SO>
<YR>1972</YR>
<VL>21</VL>
<NO>5</NO>
<PG>807-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00267922; Cochrane Library JRCT 76W1962E012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schutz-2001" NAME="Schutz 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schutz G, Berk M</AU>
<TI>Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>5</NO>
<PG>275-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21436503"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2001312880; PMID 11552770"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaskan-1975" NAME="Shaskan 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shaskan EG, Becker RE</AU>
<TI>Blood platelet monoamine oxidase activity in anergic schizophrenics</TI>
<SO>National Institute on Drug Abuse Research Monograph Series</SO>
<YR>1975</YR>
<VL>N/A</VL>
<NO>3</NO>
<PG>29-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77011721"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1233383"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiloh-2002" NAME="Shiloh 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H, Weizman A</AU>
<TI>Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>2</NO>
<PG>59-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21887027"/>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00388645"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shim-2003" NAME="Shim 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shim JC, Kelly DL, Kim YH, Yoon YR, Park JH, Shin JG, Conley RR</AU>
<TI>Fluoxetine augmentation of haloperidol in chronic schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>5</NO>
<PG>520-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2003376818"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-1998" NAME="Silver 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Silver H, Shmugliakov N</AU>
<TI>Adding fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. Evidence for a specific serotonergic mechanism</TI>
<SO>21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98346529"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9682999"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Shmugliakov N</AU>
<TI>Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double blind study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>3</NO>
<PG>208-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98278541"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9617979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-2000" NAME="Silver 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M</AU>
<TI>Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>5</NO>
<PG>257-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20445223"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2000305621; PMID 10993127"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1970" NAME="Simpson 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Krakov L, Kunz Bartholini E</AU>
<TI>A controlled trial of combined medications on behavioral and extrapyramidal effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>20-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70291110"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4917968"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1972" NAME="Simpson 1972" YEAR="1972">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Amin M, Angus JW, Edwards JG, Go SH, Lee JH</AU>
<TI>Role of antidepressants and neuroleptics in the treatment of depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>27</VL>
<NO>3</NO>
<PG>337-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72256909"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5051622"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1978" NAME="Singh 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Singh AN, Saxena B, Nelson HL</AU>
<TI>A controlled clinical study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology</TI>
<SO>Current Therapeutic Research</SO>
<YR>1978</YR>
<VL>23</VL>
<NO>4</NO>
<PG>485-501</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 61-13914"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1983" NAME="Siris 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Rifkin A, Reardon GT, November M</AU>
<TI>Comparative side effects of imipramine, benztropine, or their combination in patients receiving fluphenazine decanoate</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1983</YR>
<VL>140</VL>
<PG>1069-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83253509"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6346910"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1987" NAME="Siris 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E</AU>
<TI>Postpsychotic depression and negative symptoms: an investigation of syndromal overlap</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<NO>12</NO>
<PG>1532-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89060444"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 3057924"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Fasano Dube B</AU>
<TI>Targeted treatment of depression-like symptoms in schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1987</YR>
<VL>23</VL>
<NO>1</NO>
<PG>85-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87261760"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 3602335"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Bermanzohn PC, Gonzalez A, Mason SE, White CV, Shuwall MA</AU>
<TI>The use of antidepressants for negative symptoms in a subset of schizophrenic patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1991</YR>
<VL>16</VL>
<NO>3</NO>
<PG>331-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92131977"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1775607"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Bermanzohn PC, Mason SE, Rifkin A, Alvir JM</AU>
<TI>Adjunctive imipramine for dysphoric schizophrenic patients with past histories of cannabis abuse</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1992</YR>
<VL>27</VL>
<NO>4</NO>
<PG>539-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92350920"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1641497"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Kane JM, Frechen K, Sellew AP, Mandeli J, Fasano-Dube B</AU>
<TI>Histories of substance abuse in patients with postpsychotic depressions</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1988</YR>
<VL>29</VL>
<NO>6</NO>
<PG>550-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89169423"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1989010788; PMID 3069306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB</AU>
<TI>Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1987</YR>
<VL>44</VL>
<NO>6</NO>
<PG>533-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87212391"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 3555386"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Rifkin A, Reardon GT, Doddi SR, Foster P, Casey E</AU>
<TI>A trial of adjunctive imipramine in postpsychotic depression</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1985</YR>
<VL>21</VL>
<NO>1</NO>
<PG>114-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85166942"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2858903"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Sellew AP, Frechen K, Cooper TB, Mandell J, Casey E</AU>
<TI>Antidepressants in the treatment of post-psychotic depression in schizophrenia: drug interactions and other considerations</TI>
<SO>Clinical Chemistry</SO>
<YR>1988</YR>
<VL>34</VL>
<NO>5</NO>
<PG>837-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="88223756"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 3286051"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1993" NAME="Siris 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Mason SE, Bermanzohn PC, Shuwall MA, Aseniero MA</AU>
<TI>Adjunctive imipramine in substance abusing dysphoric schizophrenic patients</TI>
<SO>Psychopharmacology Bulletin. 32nd Annual Meeting of the New Clinical Drug Evaluation Unit: Symposium on bulimic disorders: Dual diagnosis-psychiatric comorbidity of drug dependence: Epidemiology and treatment (1992, Boca Raton, Florida)</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>1</NO>
<PG>127-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93391611"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 81-06872; PMID 8378506"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1994" NAME="Siris 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Bermanzohn PC, Mason SE, Shuwall MA</AU>
<TI>Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>2</NO>
<PG>109-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94127929"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7905256"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Cutler J, Owen K, Lang MP</AU>
<TI>Maintenance imipramine treatment following postpsychotic depression</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>1</NO>
<PG>85-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89367705"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2672073"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Cutler J, Owen K, Mason S, Gingerich S, Lang MP</AU>
<TI>Adjunctive imipramine maintenance treatment in schizophrenic patients with remitted postpsychotic depression</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>11</NO>
<PG>1495-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="90053871"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2817126"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Mason SE, Bermanzohn PC, Alvir JM, McCorry TA</AU>
<TI>Adjunctive imipramine maintenance in post psychotic depression-negative symptoms. 29th Annual Meeting of the New Clinical Drug</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>1</NO>
<PG>91-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="90319312"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 79-28466; PMID 2371372"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-2000" NAME="Siris 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siris S, Pollack S, Bermanzohn P, Stronger R</AU>
<TI>Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>3</NO>
<PG>187-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20419711"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2000302672; PMID 10962221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Pollack S, Bermanzohn PC, Stronger R</AU>
<TI>Adjunctive imipramine for a broader group of post-psychotic depressions conference abstract</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1,2&amp;3</VL>
<PG>298</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89221175"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2907629"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-St._x002d_Jean-1966" NAME="St.-Jean 1966" YEAR="1966">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>St.-Jean A, Ban TA, Noe W</AU>
<TI>The effect of iminodibenzyls in the treatment of chronic psychotic patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1966</YR>
<VL>8</VL>
<PG>164-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66127669"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4956547"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sterlin-1971" NAME="Sterlin 1971" YEAR="1971">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sterlin C, Augustin E, Ban TA, Jarrold L</AU>
<TI>Doxepin as adjuvant medication in the treatment of chronic schizophrenic patients: a comparative study</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1971</YR>
<VL>13</VL>
<NO>1</NO>
<PG>50-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71076106"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4992566"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutter-1968" NAME="Sutter 1968" YEAR="1968">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sutter JM, Luccioni H, Scotto JC, Begarra R</AU>
<TI>A controlled study of a thymoanaleptic drug (nialamide) in stabilized schizophrenics</TI>
<TO>Essai controle d'un medicament thymoanaleptique (nialamide) chez des schizophrenes stabilises</TO>
<SO>Activitas Nervosa Superior</SO>
<YR>1968</YR>
<VL>10</VL>
<NO>3</NO>
<PG>245-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69081660"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4883235"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taiminen-1997" NAME="Taiminen 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Taiminen TJ, Syvalahti E, Saarijarvi S, Niemi H, Lehto H, Ahola V, Salokangas RK</AU>
<TI>Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97323141"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9179631"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanimukai-1970" NAME="Tanimukai 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tanimukai H, Kaneko J</AU>
<TI>A double-blind, controlled study of the effects of oxypertine and carpipramine on schizophrenia</TI>
<TO>[data not available]</TO>
<SO>Seishin Igaku</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>1</NO>
<PG>55-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00267922; Cochrane Library JRCT 76W1962E012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teja-1975" NAME="Teja 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Teja JS, Grey WH, Clum JM, Warren C</AU>
<TI>Tranquilizers or anti-depressants for chronic schizophrenics: a long term study</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1975</YR>
<VL>9</VL>
<NO>4</NO>
<PG>241-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 56-04523"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vartiainen-1995" NAME="Vartiainen 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vartiainen H, Tiihonen J, Putkonen A, Koponen H, Virkkunen M, Hakola P, Lehto H</AU>
<TI>Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1995</YR>
<VL>91</VL>
<NO>5</NO>
<PG>348-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95366313"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7639092"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volterra-1990" NAME="Volterra 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volterra V, Paoli MT, Ruggeri M</AU>
<TI>Effects of amineptine in schizophrenic patients with passivity, depression, defectiveness, and chronic extrapyramidal syndromes undergoing prolonged neuroleptic treatment</TI>
<SO>Current Therapeutic Research</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>2</NO>
<PG>252-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 78-16372"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waehrens-1980" NAME="Waehrens 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waehrens J, Gerlach J</AU>
<TI>Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1980</YR>
<VL>61</VL>
<NO>5</NO>
<PG>438-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80262285"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6105762"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiner-2003" NAME="Weiner 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weiner E, Buchanan R, Gold J, Ball P, Bennett M</AU>
<TI>A comparison of bupropion SR and placebo for smoking cessation in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>305-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 2003273326"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff-1962" NAME="Wolff 1962" YEAR="1962">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolff K, Grasberger JC, Kidorf IW</AU>
<TI>Nialamide in the treatment of chronic schizophrenia in geriatric patients: a controlled study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>148-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95275743"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7756183"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yagi-1976" NAME="Yagi 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yagi G</AU>
<TI>A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients</TI>
<TO>[data not available]</TO>
<SO>Clinical Evaluation</SO>
<YR>1976</YR>
<VL>4</VL>
<NO>3</NO>
<PG>351-403</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00267922; Cochrane Library JRCT 76W1962E012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yanai-1972" NAME="Yanai 1972" YEAR="1972">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yanai N, Kamachi N, Ota H</AU>
<TI>Comparison of the clinical efficacy of y-4153 and carpipramine for schizophrenia by the double-blind method</TI>
<TO>[data not available]</TO>
<SO>Shinryo to shinyaku</SO>
<YR>1972</YR>
<VL>9</VL>
<NO>4</NO>
<PG>853-69</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00267922; Cochrane Library JRCT 76W1962E012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yi-2000" NAME="Yi 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yi MS, Li WH</AU>
<TI>Venlafaxine vs sulpiride in adjuvant treatment of negative symptoms of schizophrenia</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>377-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Cochrane Library CN-00361468"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimmermann-1970" NAME="Zimmermann 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann RL, Vestre ND, Schiele BC, Curran J</AU>
<TI>A controlled study of the effects of gamfexine in phenothiazine-treated patients</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>4</NO>
<PG>230-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70175051"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4985944"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1997" NAME="Lee 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Lee MS, Han CS, Won KS, Kim JW, Kwak DI</AU>
<TI>Fluoxetine addition to haloperidol treatment in chronic schizophrenics</TI>
<SO>6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85166942"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2858903"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-22 15:25:05 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-22 15:25:05 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" NAME="Andreasen 1984" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the assessment of negative symptoms (SANS)</SO>
<YR>1984</YR>
<PB>University of Iowa</PB>
<CY>Iowa City</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1985" NAME="Andreasen 1985" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Negative syndrome in schizophrenia: strategies for long-term management</TI>
<SO>Advance in Biochemical Psychopharmacology</SO>
<YR>1985</YR>
<VL>40</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benkert-2003" NAME="Benkert 2003" TYPE="BOOK">
<AU>Benkert O, Hippius H</AU>
<SO>Kompendium der Psychiatrischen Pharmakotherapie</SO>
<YR>2003</YR>
<PB>Springer</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indises. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crow-1980" NAME="Crow 1980" TYPE="JOURNAL_ARTICLE">
<AU>Crow TJ</AU>
<TI>Positive and negative schizophrenic symptoms and the role of dopamine</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>383-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<ED>Cochrane Collaboration</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DGPPN-1998" NAME="DGPPN 1998" TYPE="BOOK">
<AU>Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN)</AU>
<SO>Praxisleitlinien in Psychiatrie und Psychotherapie</SO>
<YR>1998</YR>
<PB>Steinkopff</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dilling-2000" NAME="Dilling 2000" TYPE="BOOK">
<AU>Dilling H, Mombour W, Schmidt MH</AU>
<SO>WHO Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien</SO>
<YR>2000</YR>
<PB>Verlag Hans Huber</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2002" MODIFIED="2008-10-22 15:22:13 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2002" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2008-10-22 15:22:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-22 15:22:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey mith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flaum-1995" NAME="Flaum 1995" TYPE="JOURNAL_ARTICLE">
<AU>Flaum M, Andreasen N</AU>
<TI>The reliability of distinguishing primary versus secondary negative symptoms</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1995</YR>
<VL>36</VL>
<NO>6</NO>
<PG>421-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleischhacker-2000" NAME="Fleischhacker 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker W</AU>
<TI>Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction</TI>
<SO>Encephale</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>1</NO>
<PG>12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale)</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Healy-2003" NAME="Healy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Healy D, Cattell D</AU>
<TI>Interface between authorship, industry and science in the domain of therapeutics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>183</VL>
<PG>22-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>In: Higgins JPT, Green S, editor(s). The Cochrane Library. Chichester, UK: John Wiley &amp; Sons, LTD</SO>
<YR>2005</YR>
<PB>John Wiley &amp; Sons, LTD</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joy-2002" MODIFIED="2008-10-22 15:20:58 +0100" MODIFIED_BY="[Empty name]" NAME="Joy 2002" TYPE="COCHRANE_REVIEW">
<AU>Joy CB, Adams CE, Lawrie SM</AU>
<TI>Haloperidol versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2008-10-22 15:20:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-22 15:20:58 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003082.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kane-2003" NAME="Kane 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Leucht S, Carpenter D, Docherty JP</AU>
<TI>The expert consensus guidelines series. Optimizing pharmacologic treatment of psychotic disorders</TI>
<SO>The Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>suppl 12</NO>
<PG>1-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Mulit-Health Systems</PB>
<CY>North Tonawanda, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-2002" MODIFIED="2008-10-22 15:25:05 +0100" MODIFIED_BY="[Empty name]" NAME="Kennedy 2002" TYPE="COCHRANE_REVIEW">
<AU>Kennedy E, Song F, Hunter R, Clarke A, Gilbody S</AU>
<TI>Risperidone versus typical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2008-10-22 15:25:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-22 15:25:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000440"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lexchin-2003" NAME="Lexchin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lexchin J, Bero LA, Djulbegovic B, Clark O</AU>
<TI>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<PG>1167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2000" NAME="Miller 2000" TYPE="OTHER">
<AU>Miller AL, Chiles JA, Chiles J, Crismon ML</AU>
<TI>Texas implementation of medication algorithms (TIMA): Guidelines for treating schizophrenia. TIMA physician procedural manual</TI>
<SO>www.mhmr.state.tx.us/centraloffice/medicaldirector/tima.html</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D, CONSORT Group</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mota-Neto-2002" MODIFIED="2008-10-22 15:23:07 +0100" MODIFIED_BY="[Empty name]" NAME="Mota Neto 2002" TYPE="COCHRANE_REVIEW">
<AU>Mota Neto JIS, Lima MS, Soares BGO</AU>
<TI>Amisulpride for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2008-10-22 15:23:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-22 15:23:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001357"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ller-1994" NAME="Möller 1994" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, Bentsen H, Eich FX, Farrow L, Fleischhacker WW</AU>
<TI>Negative symptoms in schizophrenia: considerations for clinical trials</TI>
<SO>Psychopharmacology</SO>
<YR>1994</YR>
<VL>115</VL>
<PG>221-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>790-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornley-2002" MODIFIED="2008-10-22 15:24:08 +0100" MODIFIED_BY="[Empty name]" NAME="Thornley 2002" TYPE="COCHRANE_REVIEW">
<AU>Thornley B, Adams CE, Awad G</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2008-10-22 15:24:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-22 15:24:08 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" NAME="Wahlbeck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Tuunainen A, Ahokas A, Leucht S</AU>
<TI>Drop-out rates in randomised antipsychotic drug trials</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>230-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wing-1961" NAME="Wing 1961" TYPE="JOURNAL_ARTICLE">
<AU>Wing JK Wing JK</AU>
<TI>A simple and reliable subclassification of chronic schizophrenia</TI>
<SO>Journal of Mental Science</SO>
<YR>1961</YR>
<VL>107</VL>
<PG>862-75</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Collins-1967">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - no further details.<BR/>Duration: 12 weeks.<BR/>Single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: predominantly withdrawn men with chronic schizophrenia.<BR/>N=87.<BR/>Age: not reported.<BR/>Duration of illness: not reported.<BR/>Sex: all male.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Perphenazine + amitriptyline. N=29.</P>
<P>2. Perphenazine. N=29.</P>
<P>3. Placebo. N=29.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Behaviour: Wing Scale - Form B.</P>
<P>Unable to use -<BR/>Mental state: Wing Scale - Form A (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hayashi-1997">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - no further details. <BR/>Duration: 5 weeks.<BR/>Multi-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: chronic schizophrenia with moderate to severe negative symptoms.<BR/>N=39.<BR/>Age: &gt; 50 years.<BR/>Duration of illness: at least 10 years.<BR/>Sex: 23 male, 16 female.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Continuation of neuroleptic medication + placebo. N=13.</P>
<P>2. Continuation of neuroleptic medication + mianserin. N=13.</P>
<P>3. Continuation of neuroleptic medication + trazodone. N=13.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: General (BPRS), negative symptoms (SANS).<BR/>Adverse events: AIMS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jockers-2005">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - no further details.<BR/>Duration: 12 weeks.<BR/>Single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Participants: patients with schizophrenia and &gt;20 points on the negative subscale of the PANSS.<BR/>N=29.<BR/>Age: Paroxetine group 39.9 years (mean), placebo group 39.7 years (mean).<BR/>Duration of illness: Paroxetine group 10.4 years (mean), placebo group 9.7 years (mean).<BR/>Sex: female 15, male 14.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Continuation of neuroleptic medication + paroxetine 30 mg/d. N=14.</P>
<P>2. Continuation of neuroleptic medication + placebo. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS negative.</P>
<P>Unable to use -<BR/>Global state: CGI (no SD).<BR/>Mental state: PANSS positive, HAM-D (skewed data).<BR/>Adverse events: AIMS, BAS, SAS (skewed data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Silver-1992">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - no further details.<BR/>Duration: 7 weeks (week 1-6 intervention, week 7 no intervention).<BR/>Single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: chronic schizophrenia and a score of at least "moderate" on one of the five global scales of the SANS.<BR/>N=30.<BR/>Age: fluvoxamine group 41 years (mean), placebo group 42 years (mean).<BR/>Duration of illness: history of at least 5 years of illness.<BR/>Sex: 19 male, 11 female.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Continuation of neuroleptic medication + fluvoxamine (50 mg/d in week 1, 100 mg/d in weeks 2-5, 50 mg/d in week 6). N=15.</P>
<P>2. Continuation of neuroleptic medication + placebo. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: BPRS, SANS.</P>
<P>Unable to use -<BR/>Mental state: SANS subscores affective flattening, alogia, avolition, attention, SAPS, HAM-D (skewed data).<BR/>Adverse events: SAS (skewed data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Rating at week 6 was taken as endpoint rating, because fluvoxamine or placebo were given only until this point of time.<BR/>The neuroleptic dose in the fluvoxamine group was 488 (CPZ EQ), in the placebo group 461.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Spina-1994">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - no further details.<BR/>Duration: 12 weeks.<BR/>Single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: chronic schizophrenia (DSM-III-R) with a baseline total score of at least "moderate" on one of the five global subscales of the SANS at baseline and a total score &lt; 20 on the HAMD.<BR/>N=34.<BR/>Age: fluoxetine group 46 years (mean), placebo group 45 years (mean).<BR/>Duration of illness: history of at least 5 years of illness.<BR/>Sex: 23 male, 11 female.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Continuation of neuroleptic medication + fluoxetine 20 mg/d. N=14.</P>
<P>2. Continuation of neuroleptic medication + placebo. N=16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global state: CGI-S.<BR/>Mental state: BPRS, SANS, HAMD.<BR/>Adverse events: SAS.</P>
<P>Unable to use -<BR/>Global state: CGI-I (no data for placebo group).<BR/>Mental state: SANS alogia subscore, SAPS (skewed data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>General abreviations:<BR/>n.i. - not indicated<BR/>SD - Standard Deviation</P>
<P>Diagnostic tools:<BR/>DSM-III-R - Diagnostic and Statistical Manual of Mental disorders, third edition, revised.</P>
<P>Global state scales:<BR/>CGI - Clinical Global Impression<BR/>CGI-I - Clinical Global Impression - Improvement<BR/>CGI-S - Cllinical Global Impression - Severity</P>
<P>Mental state scales:<BR/>BPRS -Brief Psychiatric Rating Scale<BR/>HAM-D - Hamilton Depression Rating Scale<BR/>IMPS - Inpatient multidimensional psychiatric scale<BR/>PRP - Patient psychotic reaction<BR/>SANS - Scale for the assessment of negative symptoms <BR/>SAPS - Scale for the assessment of positive symptoms <BR/>PANSS - Postive and Negative Symptom Scale</P>
<P>Behaviour scales:<BR/>NOSIE - Nurse Observation Scale for In-patient Evaluation</P>
<P>Side effects scales:<BR/>AIMS - Abnormal Involuntary Movement Scale<BR/>BAS - Barnes Akathisia Rating Scale<BR/>MIMS - Maryland Psychiatric Research Center Involuntary Movement Scale<BR/>SAS - Simpson and Angus Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Addington-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - computer generated random list.<BR/>Participants: people with schizophrenia in remission and major depressive episode.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anashkina-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: 'patients with schizophrenia and depressive attacks of the endogenous types'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arango-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia who are clinically stable and were required to have a minimum severity of positive or negative symptoms to be included; data from patients with negative symptoms were not reported separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arbitman-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: matched, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baldini-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and prominent depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barron-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia or involutional psychosis.<BR/>Intervention: nortriptyline versus placebo, no antipsychotic medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Becker-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Becker-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - 'computer-generated randomised code'.<BR/>Participants: people with schizophrenia.<BR/>Intervention: imipramine + chlorpromazine versus placebo + thiothixene.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Becker-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berk-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berman-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bogetto-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia and negative symptoms.<BR/>Intervention: haloperidol + amisulpride versus haloperidol + fluoxetine, no placebo-control-group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brockington-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: schizodepressive participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buchanan-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details. <BR/>Participants: people with schizophrenia, exhibiting negative or positive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Casey-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - no further details.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine + dextro-amphetamine versus chlorpromazine + imipramine versus chlorpromazine + isocarboxazid versus chlorpromazine + trifluperazine versus chlorpromazine + placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Centorrino-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: matched, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and presence of positive or negative symptoms, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and presence of positive or negative symptoms, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: neuroleptic medication + rubidium versus neuroleptic medication + placebo; rubidium is not registered as an antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Claghorn-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: matched, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clark-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random, no further details.<BR/>Participants: people with schizophrenia.<BR/>Intervention: trifluperidol versus chlorpromazine versus placebo versus 'no-drug'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cooper-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: patients with schizophrenia and significant depression of mood.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crosse-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daniel-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Decina-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - permuted block procedure.<BR/>Participants: people with schizophrenia with positive (BPRS thinking disturbance factor=sum of ratings on conceptual disorganization, unusual thought content, hallucinatory behaviour of at least 9) and negative symptoms, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Den-Boer-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic or subchronic schizophrenia with substantial negative symptoms.<BR/>Intervention: continuation of neuroleptic treatment + placebo versus continuation of neuroleptic treatment + ritanserin (was never marketed).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Deutsch-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia.<BR/>Intervention: trazodone versus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dim-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: continuation of antipsychotic medication + placebo versus continuation of antipsychotic medication + BL-KR 140 ('certain similarities to imipramine', but was never marketed).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dohner-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: noxiptilin versus non-medication therapies, no antipsychotic medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dua-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia and depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dufresne-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Evins-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fink-1963">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: psychiatric population.<BR/>Intervention: imipramine versus chlorpromazine versus placebo, no combination of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gallant-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: chlorpromazine + placebo versus chlorpromazine + BL-KR 140 ('certain similarities to imipramine', but was never marketed).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-George-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia or schizoaffective disorder, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goff-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goncalves-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with stabilised chronic schizophrenia.<BR/>Interventions: continuation of neuroleptic medication + placebo versus continuation of neuroleptic medication + EMD 16139 (never marketed).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goode-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizoaffective disorder, depressed type.<BR/>Interventions: bupropion versus bupropion + haloperidol, no just antipsychotic medication group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haider-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia on a continuous drug treatment.<BR/>Intervention: amitriptyline versus nortriptyline, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Han-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanlon-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: anergic, withdrawn psychotic patients, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanlon-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: acutely ill psychiatric patients regardless of diagnosis, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hogarty-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with defect state schizophrenia.<BR/>Intervention: no intervention with an antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jasovic_x002d_Gasic-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnson-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia with depressive episode.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kasckow-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kirli-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klein-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with early and acute mental disorders.<BR/>Intervention: placebo versus imipramine versus chlorpromazine, no combination group of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klein-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with some form of psychotic disturbance.<BR/>Intervention: no combination group of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Komori-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: no combination of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kondo-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - no further details.<BR/>Participants: people with schizophrenia.<BR/>Interventions: no combination of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kornhuber-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia with positive and negative symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kothari-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Intervention: perphenazine versus proketazine versus nialamide versus MO-482, no combination of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kramer-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kurland-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: newly admitted, acutely ill patients, suitable for tranquillizing drug treatment, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kurland-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lapolla-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random (and numbered serially, all even numbered patients received the even numbered code, all uneven numbered patients received the odd numbered coded medication).<BR/>Participants: people with schizophrenia.<BR/>Intervention: chlorpromazine versus perphenazine+amitriptyline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lauriello-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia with positive or negative symptoms, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lehmann-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia acute and chronic, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lehmann-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maeda-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia and/or depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Masciocchi-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably matched.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: sulpiride versus chlorimipramine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Michaux-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, acutely ill, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mulholland-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia and significant depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muller-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with major depressive as well as paranoid and/or hallucinatory symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nussbaum-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic anergic schizophrenia.<BR/>Intervention: modaline versus placebo, no antipsychotic medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ogata-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: imipramine versus trimipramine versus carpipramine, no antipsychotic medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oltman-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: patients with subacute or recurrent exacerbations of schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Park-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Intervention: no antipsychotic treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pishkin-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Potkin-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, schizoaffective disorder or bipolar disorder, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poyurovsky-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poyurovsky-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with a first episode of schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poyurovsky-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - the participants were allocated to entries of a table of random numbers to receive intervention or control group treatment.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poyurovsky-2003a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - according to entries on a table of random numbers, the participants were allocated to intervention or control group.<BR/>Participants: people with schizophrenia and neuroleptic-induced akathisia, no 'predominantly negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prusoff-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reinhardt-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: paired, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reznik-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and obsessive-compulsive symptoms, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robak-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: matched, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosini-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salokangas-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: unselected patients with chronic schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Samejima-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia.<BR/>Intervention: no combination of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schutz-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shaskan-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia and depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shiloh-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - 'according to a table of random numbers'.<BR/>Participants: people with schizophrenia, hospitalised following an acute psychotic exacerbation of the disorder, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shim-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>Participants: people with chronic schizophrenia, severely psychotic, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silver-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia with negative symptoms.<BR/>Intervention: regular treatment + fluvoxamine versus regular treatment + maprotiline, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silver-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia with negative and positive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simpson-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simpson-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: 'divided into two groups, equated for age and length of hospitalisation', not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singh-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants:people with chronic schizophrenia and depressive symptoms, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with a post psychotic depression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia or schizoaffective disorder and post psychotic depression syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia or schizoaffective disorder and post psychotic depression syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia or schizoaffective disorder and post psychotic depression syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia or schizoaffective disorder and post psychotic depression syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-St._x002d_Jean-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: chronic psychotic patients.<BR/>Intervention: imipramine versus demethylimipramine versus opipramol, no antipsychotic medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sterlin-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutter-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taiminen-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: unselected people with chronic schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tanimukai-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: no combination of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teja-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vartiainen-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and aggressive episodes, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Volterra-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia with depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waehrens-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised - cross-over.<BR/>Participants: people with schizophrenia.<BR/>Interventions: continuation of neuroleptics + maprotiline versus continuation of neuroleptics + placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weiner-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably not randomised.<BR/>Participants: people with schizophrenia, no 'predominant negative symptoms'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolff-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: nialamide, no antipsychotic medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yagi-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with chronic schizophrenia and depressive symptoms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yanai-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Interventions: no combination of antipsychotic and antidepressive medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yi-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random - no further details.<BR/>Participants: people with schizophrenia and negative symptoms.<BR/>Interventions: comparison of venlafaxine and sulpiride as adjuvant treatment to antipsychotic medication, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zimmermann-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised to a modified cross-over design, in which each patient had five two-week trials of each treatment condition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Lee-1997">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Collins-1967">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hayashi-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jockers-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Silver-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Spina-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Suggested design of study</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Type of study</P>
</TH>
<TH>
<P>Patient</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Allocation: randomised, with sequence generation and concealment of allocation clearly described.<BR/>Blindness: double, tested.<BR/>Design: parallel group.<BR/>Duration: 6 and 12 months.</P>
</TD>
<TD>
<P>Diagnosis: any person with schizophrenia<BR/>History: with pronounced negative symptoms + no/minimal positive symptoms + no depressive symptoms.<BR/>N=300.*<BR/>Age: any.<BR/>Sex: both.</P>
</TD>
<TD>
<P>1. Second generation antipsychotic + SSRI. N=150.<BR/>2. Second generation antipsychotic + placebo. N=150.<BR/>
</P>
</TD>
<TD>
<P>Service use: readmission/relapse**, time in hospital, use of other psychotropic medications.<BR/>Global response: CGI (binary).**<BR/>Mental state: CGI (binary).<BR/>Serious adverse effects: any**, list.<BR/>Satisfaction: patient, staff and carers (binary outcome).<BR/>Quality of life: binary outcome.<BR/>Economic outcomes.</P>
</TD>
<TD>
<P>* Size of study with sufficient power to highlight ~10% difference between groups for primary outcome.<BR/>** Primary outcome.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>ANTIDEPRESSANTS + ANTIPSYCHOTICS VERSUS PLACEBO + ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="0.08442510926109939" CI_END="15.788424712076107" CI_START="0.7470199799979595" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4342784850117183" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.1983388004971132" LOG_CI_START="-0.12666778227185713" LOG_EFFECT_SIZE="0.5358355091126279" METHOD="MH" NO="1" P_CHI2="0.958665991097954" P_Q="0.9589503644987524" P_Z="0.11291470142439008" Q="0.08383192817049259" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="94" TOTAL_2="94" WEIGHT="300.0" Z="1.585227293442892">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.039968158429385" CI_START="0.3456225424410365" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="1.4156404488428953" LOG_CI_START="-0.4613979394035703" LOG_EFFECT_SIZE="0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.3190558719048162" STUDIES="3" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.9963999472410479">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76106" O_E="0.0" SE="0.0" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76107" O_E="0.0" SE="0.0" STUDY_ID="STD-Silver-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="26.039968158429385" CI_START="0.3456225424410365" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4156404488428953" LOG_CI_START="-0.4613979394035703" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="76108" O_E="0.0" SE="1.1025816407458469" STUDY_ID="STD-Spina-1994" TOTAL_1="17" TOTAL_2="17" VAR="1.2156862745098038" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="96.9971877024067" CI_START="0.25773943134002514" DF="0" EFFECT_SIZE="4.999999999999998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="1.9867591426885958" LOG_CI_START="-0.5888191340165585" LOG_EFFECT_SIZE="0.6989700043360186" NO="2" P_CHI2="1.0" P_Z="0.2874172339006109" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.0638046198502171">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76109" O_E="0.0" SE="0.0" STUDY_ID="STD-Silver-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="96.9971877024067" CI_START="0.2577394313400252" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9867591426885958" LOG_CI_START="-0.5888191340165584" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="76110" O_E="0.0" SE="1.5129074290546958" STUDY_ID="STD-Spina-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.288888888888889" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.84318997239909" CI_START="0.1307318850798215" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="1.8378609859337425" LOG_CI_START="-0.8836184764944177" LOG_EFFECT_SIZE="0.47712125471966244" NO="3" P_CHI2="1.0" P_Z="0.4919381264121142" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="0.6872294929425984">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="68.84318997239909" CI_START="0.1307318850798215" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8378609859337425" LOG_CI_START="-0.8836184764944177" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="76111" O_E="0.0" SE="1.5986105077709065" STUDY_ID="STD-Spina-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.555555555555556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.3913733605228742" CI_START="-1.6086266394771258" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0012805385594994861" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="14" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="3.220305943597653">
<NAME>Clinical response: 1. Average improvement (CGI endpoint score, high=poor)</NAME>
<GROUP_LABEL_1>+ anitdepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3913733605228742" CI_START="-1.6086266394771258" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="3.8" ORDER="76112" SD_1="1.1" SD_2="0.4" SE="0.3105295017040594" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.25445396402241627" CI_START="-1.5455460359775834" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.006285181643167848" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="14" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="2.7325202042558927">
<NAME>Clinical response: 2. Average severity (CGI endpoint score, high=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.25445396402241627" CI_START="-1.5455460359775834" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="4.3" ORDER="76113" SD_1="0.9" SD_2="0.9" SE="0.32936627462012996" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.885016521672364" CI_END="3.5034626643649887" CI_START="-13.273561640001759" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.885049487818385" ESTIMABLE="YES" I2="87.31771839346881" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.004984620664424844" P_Q="1.0" P_Z="0.2537098069750424" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="32.290092261904796" TOTALS="YES" TOTAL_1="29" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="1.1413848946177902">
<NAME>Mental state: 1a. General - Average endpoint score (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0754652067119026" CI_START="-3.0754652067119026" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="9.5" ORDER="76114" SD_1="2.9" SD_2="2.9" SE="1.0589302778433212" STUDY_ID="STD-Silver-1992" TOTAL_1="15" TOTAL_2="15" WEIGHT="54.82500595560019"/>
<CONT_DATA CI_END="-3.9675388085470598" CI_START="-15.232461191452943" EFFECT_SIZE="-9.600000000000001" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="44.6" ORDER="76115" SD_1="8.6" SD_2="6.9" SE="2.8737574954851604" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="45.17499404439981"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.006713630591591" CI_START="-3.8067136305915903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9599876164652889" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.05016912345948583">
<NAME>Mental state: 1b. General - Average change score (BPRS total, low=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.006713630591591" CI_START="-3.8067136305915903" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.6" ORDER="76116" SD_1="6.1" SD_2="3.8" SE="1.9932578666788006" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.20671363059159" CI_START="-3.6067136305915906" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.8803643362984526" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.15050737037845735">
<NAME>Mental state: 2a. i. Positive symptoms - Average change score (BPRS positive subscale, low=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.20671363059159" CI_START="-3.6067136305915906" EFFECT_SIZE="0.3" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.2" ORDER="76117" SD_1="6.1" SD_2="3.8" SE="1.9932578666788006" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.28214549517430876" CI_START="-2.88214549517431" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.10730144960216269" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="14" UNITS="" WEIGHT="100.00000000000001" Z="1.6104417625771874">
<NAME>Mental state: 2a. ii. Positive symptons - Average endpoint score (PANSS positive subscale, high=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.28214549517430876" CI_START="-2.88214549517431" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="9.3" ORDER="76118" SD_1="1.2" SD_2="2.7" SE="0.8072319224506528" STUDY_ID="STD-Jockers-2005" TOTAL_1="11" TOTAL_2="14" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.08" NO="8" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Mental state: 2a. iii. Positive symptoms - Average endpoint score (SAPS total, high =poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="730" STUDY_ID="STD-Silver-1992">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>1.6</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>0.9</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="731" STUDY_ID="STD-Spina-1994">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P>6.4</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>14.2</P>
</TD>
<TD>
<P>7.0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="2.470474500887594" CI_END="0.9570955352696431" CI_START="0.33941397994382877" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5699575465000343" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="30" I2="59.52194610222775" I2_Q="52.89253270859328" ID="CMP-001.09" LOG_CI_END="-0.019044709694818043" LOG_CI_START="-0.4692702737230445" LOG_EFFECT_SIZE="-0.24415749170893122" METHOD="MH" NO="9" P_CHI2="0.11600315136481032" P_Q="0.14512054201394664" P_Z="0.03352171509040663" Q="2.1228056983280412" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08517368314804218" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.1257784032678364">
<NAME>Mental state: 2b. i. Negative symptoms - Improvement score (SANS, 20% reduction)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7444269433332491" CI_START="0.24673135629043463" DF="0" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-0.12817791666808948" LOG_CI_START="-0.6077756539210993" LOG_EFFECT_SIZE="-0.36797678529459443" NO="1" P_CHI2="1.0" P_Z="0.0026331163884551066" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="42.50766790834504" Z="3.0076090452601782">
<NAME>Less than 20% reduction</NAME>
<DICH_DATA CI_END="0.7444269433332491" CI_START="0.24673135629043463" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.12817791666808948" LOG_CI_START="-0.6077756539210993" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="76121" O_E="0.0" SE="0.2817180849095055" STUDY_ID="STD-Spina-1994" TOTAL_1="17" TOTAL_2="17" VAR="0.07936507936507936" WEIGHT="42.50766790834504"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0232159511120456" CI_START="0.48396323578431405" DF="0" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.009967301824335202" LOG_CI_START="-0.31518762823665186" LOG_EFFECT_SIZE="-0.15261016320615833" NO="2" P_CHI2="1.0" P_Z="0.06579724103331758" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="57.492332091654966" Z="1.8398024812525404">
<NAME>Less than 30% reduction</NAME>
<DICH_DATA CI_END="1.0232159511120456" CI_START="0.48396323578431405" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.009967301824335202" LOG_CI_START="-0.31518762823665186" LOG_EFFECT_SIZE="-0.15261016320615833" ORDER="76122" O_E="0.0" SE="0.19099761546068594" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" VAR="0.03648008911166806" WEIGHT="57.492332091654966"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.7646506891485796" CI_END="-7.921998085523869" CI_START="-19.925937718725557" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.923967902124712" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.38187704627629127" P_Q="1.0" P_Z="5.443672052897374E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="4.546919835313645">
<NAME>Mental state: 2b. ii. Negative symptoms - Average endpoint score (SANS total, high=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7646506891485796" CI_END="-7.921998085523869" CI_START="-19.925937718725557" DF="1" EFFECT_SIZE="-13.923967902124712" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="0.38187704627629127" P_Z="5.443672052897374E-6" STUDIES="2" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0" Z="4.546919835313645">
<NAME>SANS total score at endpoint (high=poor)</NAME>
<CONT_DATA CI_END="-4.139239796859732" CI_START="-19.460760203140268" EFFECT_SIZE="-11.8" ESTIMABLE="YES" MEAN_1="27.3" MEAN_2="39.1" ORDER="76123" SD_1="10.4" SD_2="11.0" SE="3.9086229459150106" STUDY_ID="STD-Silver-1992" TOTAL_1="15" TOTAL_2="15" WEIGHT="61.38240177955069"/>
<CONT_DATA CI_END="-7.6416891894771375" CI_START="-26.958310810522857" EFFECT_SIZE="-17.299999999999997" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="59.3" ORDER="76124" SD_1="15.3" SD_2="11.0" SE="4.927800146689624" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="38.61759822044931"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.563400663440338" CI_START="-7.103400663440337" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2699999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.3573144686333837" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.9204944002591978">
<NAME>Mental state: 2b. iii. Negative symptoms - Average endpoint score (PANSS negative subscale, high=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.563400663440338" CI_START="-7.103400663440337" EFFECT_SIZE="-2.2699999999999996" ESTIMABLE="YES" MEAN_1="23.09" MEAN_2="25.36" ORDER="76125" SD_1="5.47" SD_2="6.86" SE="2.4660660611958103" STUDY_ID="STD-Jockers-2005" TOTAL_1="11" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.8961452130849707" CI_START="-11.09614521308497" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.16517526214841938" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.3878745060569075">
<NAME>Mental state: 2b. iv. Negative symptoms - Average change score (SANS total , low=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8961452130849707" CI_START="-11.09614521308497" EFFECT_SIZE="-4.6" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-1.2" ORDER="76126" SD_1="8.4" SD_2="8.5" SE="3.3144207058526254" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.0878414551343" CI_END="-1.219677352202208" CI_START="-3.5021383666420665" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.360907859422137" ESTIMABLE="YES" I2="73.48858674122118" I2_Q="74.7538778354001" ID="CMP-001.13" NO="13" P_CHI2="0.004522461782503817" P_Q="0.007794853507376742" P_Z="5.020865187474707E-5" Q="11.883013083912736" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.605505583661666" TOTALS="SUB" TOTAL_1="71" TOTAL_2="79" UNITS="" WEIGHT="400.0" Z="4.0546535918998226">
<NAME>Mental state: 2b. v. Negative symptoms - Various average endpoint scores (SANS subscale, high=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.6300362574544343" CI_START="-10.369963742545565" DF="0" EFFECT_SIZE="-7.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="1.0" P_Z="4.677446009563663E-5" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0" Z="4.071185609082224">
<NAME>Affective flattening</NAME>
<CONT_DATA CI_END="-3.6300362574544343" CI_START="-10.369963742545565" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="18.8" ORDER="76127" SD_1="4.1" SD_2="5.3" SE="1.7194008507949174" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9578482592578825" CI_START="-5.042151740742117" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="1.0" P_Z="0.003986057658488133" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0" Z="2.879263002994778">
<NAME>Avolition</NAME>
<CONT_DATA CI_END="-0.9578482592578825" CI_START="-5.042151740742117" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="11.1" ORDER="76128" SD_1="2.8" SD_2="2.9" SE="1.0419332992087353" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.141625289896802" CI_END="0.2663990760650967" CI_START="-5.416643328938662" DF="1" EFFECT_SIZE="-2.5751221264367823" ESTIMABLE="YES" I2="68.16934205311135" ID="CMP-001.13.03" NO="3" P_CHI2="0.07631803483123545" P_Z="0.07569783236189276" STUDIES="2" TAU2="2.8665208333333303" TOTAL_1="29" TOTAL_2="31" WEIGHT="100.0" Z="1.7762129028509177">
<NAME>Anhedonia</NAME>
<CONT_DATA CI_END="1.2284284146765105" CI_START="-3.4284284146765134" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="14.3" ORDER="76129" SD_1="3.1" SD_2="3.4" SE="1.1879955106536948" STUDY_ID="STD-Silver-1992" TOTAL_1="15" TOTAL_2="15" WEIGHT="49.133719778042014"/>
<CONT_DATA CI_END="-1.7950405173924389" CI_START="-6.204959482607562" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="13.3" ORDER="76130" SD_1="3.5" SD_2="2.5" SE="1.125" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="50.86628022195799"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2785872880920608" CI_START="-2.278587288092061" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.04" NO="4" P_CHI2="1.0" P_Z="0.5816412327080013" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0" Z="0.5509889780676891">
<NAME>Attention</NAME>
<CONT_DATA CI_END="1.2785872880920608" CI_START="-2.278587288092061" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="6.6" ORDER="76131" SD_1="3.0" SD_2="1.7" SE="0.9074591686996957" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.885696479770309" CI_END="0.11439907220451995" CI_START="-1.739432979487435" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8125169536414575" ESTIMABLE="YES" I2="49.27524778234287" I2_Q="49.27524778234287" ID="CMP-001.14" NO="14" P_CHI2="0.09585620490124014" P_Q="0.09585620490124014" P_Z="0.08578436956450612" Q="7.885696479770309" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.1210231865563296" TOTALS="SUB" TOTAL_1="65" TOTAL_2="65" UNITS="" WEIGHT="500.0" Z="1.718067140453216">
<NAME>Mental State: 2b. vi. Negative symptoms - Various change scores (SANS subscale, low=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.31940870833730006" CI_START="-5.9194087083373" DF="0" EFFECT_SIZE="-2.8" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" NO="1" P_CHI2="1.0" P_Z="0.07853073448193783" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="1.7592754492364353">
<NAME>Affective flattening</NAME>
<CONT_DATA CI_END="0.31940870833730006" CI_START="-5.9194087083373" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-0.2" ORDER="76132" SD_1="4.3" SD_2="3.8" SE="1.5915643006416431" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8557214006714271" CI_START="-5.1442785993285725" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" NO="2" P_CHI2="1.0" P_Z="0.0061042066741853335" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="2.7421305960248374">
<NAME>Alogia</NAME>
<CONT_DATA CI_END="-0.8557214006714271" CI_START="-5.1442785993285725" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="0.2" ORDER="76133" SD_1="3.4" SD_2="2.0" SE="1.094039796772986" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.2172356852551123" CI_START="-2.017235685255112" DF="0" EFFECT_SIZE="0.1" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.03" NO="3" P_CHI2="1.0" P_Z="0.9262437178315297" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.09257183780670561">
<NAME>Avolition</NAME>
<CONT_DATA CI_END="2.2172356852551123" CI_START="-2.017235685255112" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.2" ORDER="76134" SD_1="3.4" SD_2="1.9" SE="1.0802421380982492" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3745939624597696" CI_START="-1.9745939624597697" DF="0" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.04" NO="4" P_CHI2="1.0" P_Z="0.725495743001368" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.3511234415883917">
<NAME>Anhedonia</NAME>
<CONT_DATA CI_END="1.3745939624597694" CI_START="-1.9745939624597695" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.2" ORDER="76135" SD_1="1.8" SD_2="2.5" SE="0.8544003745317531" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.246347705542134" CI_START="-1.6463477055421343" DF="0" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.05" NO="5" P_CHI2="1.0" P_Z="0.7625767910377542" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.30209874303946027">
<NAME>Attention</NAME>
<CONT_DATA CI_END="2.246347705542134" CI_START="-1.646347705542134" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-1.1" ORDER="76136" SD_1="2.1" SD_2="2.9" SE="0.9930527912220206" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.15" NO="15" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Mental state: 2b. vii. Negative symptoms - Various average endpoint scores (SANS subscale, high=poor, skewed)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.15.01" NO="1" STUDIES="1">
<NAME>Affective flattening</NAME>
<OTHER_DATA ORDER="748" STUDY_ID="STD-Silver-1992">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>4.8</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>10.9</P>
</TD>
<TD>
<P>3.1</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.15.02" NO="2" STUDIES="2">
<NAME>Alogia</NAME>
<OTHER_DATA ORDER="749" STUDY_ID="STD-Silver-1992">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>1.9</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>6.7</P>
</TD>
<TD>
<P>2.7</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="750" STUDY_ID="STD-Spina-1994">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>6.7</P>
</TD>
<TD>
<P>4.2</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>9.4</P>
</TD>
<TD>
<P>3.4</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.15.03" NO="3" STUDIES="1">
<NAME>Avolition</NAME>
<OTHER_DATA ORDER="751" STUDY_ID="STD-Silver-1992">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>1.8</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>3.9</P>
</TD>
<TD>
<P>4.2</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.15.04" NO="4" STUDIES="1">
<NAME>Attention</NAME>
<OTHER_DATA ORDER="752" STUDY_ID="STD-Silver-1992">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>3.8</P>
</TD>
<TD>
<P>3.9</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>3.5</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.4585839321971097" CI_START="-5.54141606780289" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.02068812390629968" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="14" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="2.3136282280230716">
<NAME>Mental state: 3a. Depression - Average endpoint score (HAM-D total, high=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4585839321971097" CI_START="-5.54141606780289" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="11.7" ORDER="76142" SD_1="3.4" SD_2="3.7" SE="1.2966646774375732" STUDY_ID="STD-Spina-1994" TOTAL_1="14" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.17" NO="17" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Mental state: 3b. Depression - Average endpoint score (HAM-D total, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="754" STUDY_ID="STD-Jockers-2005">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>4.7</P>
</TD>
<TD>
<P>2.2</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>6.2</P>
</TD>
<TD>
<P>3.5</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="755" STUDY_ID="STD-Silver-1992">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>2.0</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>2.6</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4669944684965225" CI_START="-2.3269944684965225" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.93" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.1919687311662001" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="1.3047771818194482">
<NAME>Behaviour: 1. Social withdrawal - Average change score (Wing Scale Form B, low=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4669944684965225" CI_START="-2.3269944684965225" EFFECT_SIZE="-0.93" ESTIMABLE="YES" MEAN_1="-1.55" MEAN_2="-0.62" ORDER="76145" SD_1="3.27" SD_2="2.01" SE="0.7127653770762302" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.2106608555145999" CI_START="-1.5893391444854001" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.19" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.010499620871967198" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="2.558925603162826">
<NAME>Behaviour: 2. Socially embarrassing - Average change score (Wing Scale Form B, low=poor)</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2106608555145999" CI_START="-1.5893391444854001" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="-0.76" MEAN_2="0.14" ORDER="76146" SD_1="1.52" SD_2="1.13" SE="0.35171010790137947" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.074609185068446" CI_END="4.8986516348604106" CI_START="0.6593445204658619" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.797192007860136" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="6.94291339634268" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.6900765559214769" LOG_CI_START="-0.18088759869908635" LOG_EFFECT_SIZE="0.2545944786111952" METHOD="MH" NO="20" P_CHI2="0.29990707700070873" P_Q="1.0" P_Z="0.2518583153606313" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08772806886879538" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.00000000000001" Z="1.1458474062186503">
<NAME>Adverse events: 1. General - at least one event</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.67329787527168" CI_START="0.6125285986597502" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5650561476051313" LOG_CI_START="-0.21287362949376892" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="76147" O_E="0.0" SE="0.4569598018823958" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" VAR="0.20881226053639845" WEIGHT="88.26570644874005"/>
<DICH_DATA CI_END="123.34726157573661" CI_START="0.3972524349064162" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0911295121901796" LOG_CI_START="-0.40093343216166605" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="76148" O_E="0.0" SE="1.4638501094227996" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" VAR="2.1428571428571423" WEIGHT="11.734293551259965"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.214595346839554" CI_END="1.1383272155799484" CI_START="0.8887816167419605" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0058450691058345" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="51.050434890237476" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.05626711925952033" LOG_CI_START="-0.05120493677431294" LOG_EFFECT_SIZE="0.0025310912426037275" METHOD="MH" NO="21" P_CHI2="0.06937822793409931" P_Q="0.7222099359637535" P_Z="0.9264447215541749" Q="2.0736769114279103" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.8998777374122446" TOTALS="SUB" TOTAL_1="154" TOTAL_2="154" WEIGHT="500.0" Z="0.09231883822016479">
<NAME>Adverse events: 2a. Movement disorders - Various</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="96.9971877024067" CI_START="0.25773943134002514" DF="0" EFFECT_SIZE="4.999999999999998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.21.01" LOG_CI_END="1.9867591426885958" LOG_CI_START="-0.5888191340165585" LOG_EFFECT_SIZE="0.6989700043360186" NO="1" P_CHI2="1.0" P_Z="0.2874172339006109" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.0638046198502171">
<NAME>Any extrapyramidal event</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76149" O_E="0.0" SE="0.0" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="96.9971877024067" CI_START="0.2577394313400252" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9867591426885958" LOG_CI_START="-0.5888191340165584" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="76150" O_E="0.0" SE="1.5129074290546958" STUDY_ID="STD-Spina-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.288888888888889" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.84318997239909" CI_START="0.1307318850798215" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="1.8378609859337425" LOG_CI_START="-0.8836184764944177" LOG_EFFECT_SIZE="0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.4919381264121142" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="0.6872294929425984">
<NAME>Akathisia</NAME>
<DICH_DATA CI_END="68.84318997239909" CI_START="0.1307318850798215" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8378609859337425" LOG_CI_START="-0.8836184764944177" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="76151" O_E="0.0" SE="1.5986105077709065" STUDY_ID="STD-Spina-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.555555555555556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6873666314393949" CI_END="4.238630478199441" CI_START="0.20959395886200505" DF="1" EFFECT_SIZE="0.9425451406054642" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.21.03" LOG_CI_END="0.6272255566309567" LOG_CI_START="-0.6786212392012204" LOG_EFFECT_SIZE="-0.025697841285131848" NO="3" P_CHI2="0.40706191744335307" P_Z="0.9385117672935759" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.07714050922365308">
<NAME>Parkinsonism</NAME>
<DICH_DATA CI_END="3.699119357300525" CI_START="0.1201487169013067" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5680983446651372" LOG_CI_START="-0.9202808627764997" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="76152" O_E="0.0" SE="0.8742813140471173" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" VAR="0.764367816091954" WEIGHT="76.97634160415465"/>
<DICH_DATA CI_END="68.84318997239909" CI_START="0.1307318850798215" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8378609859337425" LOG_CI_START="-0.8836184764944177" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="76153" O_E="0.0" SE="1.5986105077709065" STUDY_ID="STD-Spina-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.555555555555556" WEIGHT="23.023658395845352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.84318997239909" CI_START="0.1307318850798215" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.21.04" LOG_CI_END="1.8378609859337425" LOG_CI_START="-0.8836184764944177" LOG_EFFECT_SIZE="0.47712125471966244" NO="4" P_CHI2="1.0" P_Z="0.4919381264121142" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="0.6872294929425984">
<NAME>Tremor</NAME>
<DICH_DATA CI_END="68.84318997239909" CI_START="0.1307318850798215" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8378609859337425" LOG_CI_START="-0.8836184764944177" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="76154" O_E="0.0" SE="1.5986105077709065" STUDY_ID="STD-Spina-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.555555555555556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1325342689505136" CI_START="0.8829754890566542" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-001.21.05" LOG_CI_END="0.054051352045522444" LOG_CI_START="-0.054051352045522395" LOG_EFFECT_SIZE="0.0" NO="5" P_CHI2="1.0" P_Z="1.0" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="100.0" Z="0.0">
<NAME>Use of anticholinergics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76155" O_E="0.0" SE="0.0" STUDY_ID="STD-Collins-1967" TOTAL_1="29" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1325342689505136" CI_START="0.8829754890566542" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.054051352045522444" LOG_CI_START="-0.054051352045522395" LOG_EFFECT_SIZE="0.0" ORDER="76156" O_E="0.0" SE="0.06350006350009522" STUDY_ID="STD-Silver-1992" TOTAL_1="15" TOTAL_2="15" VAR="0.0040322580645161255" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.22" NO="22" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Adverse events: 2b. Movement disorders - Average endpoint score (SAS total, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="768" STUDY_ID="STD-Jockers-2005">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>1.2</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>0.6</P>
</TD>
<TD>
<P>1.4</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="769" STUDY_ID="STD-Silver-1992">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>1.3</P>
</TD>
<TD>
<P>1.0</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>1.3</P>
</TD>
<TD>
<P>1.2</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.23" NO="23" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events: 2c. Movement disorders - Average endpoint score (AIMS total, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="770" STUDY_ID="STD-Jockers-2005">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>0.8</P>
</TD>
<TD>
<P>1.9</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>2.7</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.24" NO="24" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events: 2d. Movement disorders - Average endpoint score (BAS akathisia, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="771" STUDY_ID="STD-Jockers-2005">
<TR>
<TD>
<P>+ antidepressants</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>2.1</P>
</TD>
</TR>
<TR>
<TD>
<P>+ placebo</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>0.8</P>
</TD>
<TD>
<P>2.1</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.054852293944297664" CI_END="33.371566864066445" CI_START="0.46247546181900673" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9285532702361303" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="1.5233765981574214" LOG_CI_START="-0.3349113052585968" LOG_EFFECT_SIZE="0.5942326464494123" METHOD="MH" NO="25" P_CHI2="0.8148253183253941" P_Q="0.8152777270392357" P_Z="0.21002670372787646" Q="0.054579673065878284" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="26" WEIGHT="200.0" Z="1.2534920808963945">
<NAME>Adverse events: 3. Sedative effects</NAME>
<GROUP_LABEL_1>+ antidepressants</GROUP_LABEL_1>
<GROUP_LABEL_2>+ placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.51227986921384" CI_START="0.13330908121359522" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.4892273981416261" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.6915381840105491">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="76161" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="95.0161400460208" CI_START="0.26311319306268716" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="1.9777973835788356" LOG_CI_START="-0.5798573749067983" LOG_EFFECT_SIZE="0.6989700043360189" NO="2" P_CHI2="1.0" P_Z="0.2840527612210265" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="1.0712595437106938">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="95.0161400460208" CI_START="0.26311319306268716" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9777973835788356" LOG_CI_START="-0.5798573749067983" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="76162" O_E="0.0" SE="1.5023790657297034" STUDY_ID="STD-Hayashi-1997" TOTAL_1="13" TOTAL_2="13" VAR="2.2571428571428567" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>